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The ideal goal of cancer chemotherapy is to destroy cancer cells without harming 
healthy cells. Most current anticancer drugs cannot greatly differentiate between 
cancerous and normal cells. This leads to systemic toxicity and adverse effects. 
Targeted delivery of anticancer agents could offer a more efficient and less harmful 
solution to overcome this drawback. The purpose of this project was to confirm the 
hypothesis that conjugation of WGA to PLGA nanoparticles loaded with paclitaxel 
(WNP) could improve the delivery of paclitaxel to colonic cancer cells. 
 
Glycosylation patterns of representative colon cancer cells (Caco-2 and HT-29 cells) 
and normal cells (colon fibroblasts, CCD-18Co cells) were first investigated. Our 
results confirmed the higher expression levels of WGA-binding glycoproteins 
(N-acetylglucosamine and sialic acid) in the Caco-2 and HT-29 cells, than in the 
CCD-18Co cells. Most of the WGA-recognizable glycoproteins in the Caco-2 and 
HT-29 cells had molecular weight > 75 kDa, whereas the CCD-18Co cells showed an 
apparent lack of expression of such large proteins. The ranking order of expression of 
WGA-recognizable glycoproteins in the three cell lines was HT-29 > Caco-2 > 
CCD-18Co cells. 
 
In vitro cytotoxicity and cellular uptake studies were then carried out to evaluate the 
potential of WGA for targeted activity against the colon cell models. WGA exhibited 
IX 
 
different degrees of cytotoxicity against the Caco-2, HT-29 and CCD-18Co cells, but 
showed anti-proliferative activity in all 3 cell lines at concentrations ≥ 50 µg/ml. 
Cellular uptake of fWGA ranked in the order of Caco-2 > HT-29 > CCD-18Co cells. 
The higher binding of fWGA to the malignant cells may be associated with the greater 
expression of WGA-recognizable glycoproteins in these cells relative to the colon 
fibroblast cells. 
 
WGA was conjugated onto the surface of paclitaxel-loaded PLGA nanoparticles to 
prepare the WNP formulation. Cellular uptake and cytotoxicity of WNP were 
evaluated in the three colon cell lines. In vitro anti-proliferation studies suggested that 
the incorporation of WGA enhanced the cytotoxicity of the paclitaxel-loaded PLGA 
nanoparticles against the cancerous Caco-2 and HT-29 cells. Paclitaxel uptake from 
the WNP formulation at 2h incubation was the highest in the Caco-2 cells compared 
to the other two cell lines. Caco-2 and HT-29 cells showed preferential uptake of 
WNP compared to PNP, suggesting that WGA conjugation to the PLGA nanoparticles 
was advantageous in facilitating the nanoparticle uptake by the cultured colon cancer 
cells. The greater efficacy of WNP correlated well with the higher cellular uptake and 
sustained intracellular retention of paclitaxel associated with the formulation, which 
again might be attributed to the over-expression of N-acetyl-D-glucosamine- 
containing glycoprotein on the colon cell surface. About 30% of the endocytosed 





indicated successful escape of the WNP from the endo-lysosome compartment into 
the cytosol with increasing incubation time. 
 
To evaluate the effect of mucin glycoprotein on the cellular uptake of WNP, the 
uptake experiments were repeated using a mucin-secreting cell line, LS174T. The 
LS174 cells showed no significant differences in paclitaxel uptake from the WNP 
formulation on day 3 of culture compared to day 6 of culture, despite the significantly 
higher production of mucin by day 6. The presence of mucin may therefore not be a 
barrier for the cellular uptake of WGA-conjugated nanoparticles. FRAP results 
showed that fWNP was capable of diffusing in the mucin layer, although the diffusion 
rate was slowed down by the viscous mucin. This diffusion capability allowed the 
fWNP to remain mobile in the mucin layer and enabled the particles to be transported 
into the cells. Interaction between the mucin glycoprotein and WGA is postulated to 
serve as a bridge between WNP and the colon cancer cells under the mucin layer. 
 
On the basis of these results, it may be concluded that WNP has the potential to be 
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Chapter 1 Introduction 
 
1.1 Chemotherapy for colon cancer 
Successful systemic cancer chemotherapy, first developed in 1946, was highlighted in 
a review by Gilman and Philips (Gilman & Philips, 1946) which also marked the 
beginning of modern cancer chemotherapy (Pratt et al., 1994). Chemotherapy is often 
needed for colon cancer patients after surgical removal of the tumor in order to reduce 
the risk of recurrence. Various anticancer agents are used, depending on the stages of 
colon cancer and patient condition. While most are highly effective, anticancer agents 
are also potent agents which can cause serious side effects. Unfortunately, the 
systemic administration of most chemotherapeutic drugs is non-discriminative, 
causing both cancerous and healthy tissues to be concomitantly exposed to the drugs, 
resulting in high mortality and morbidity. This provides the impetus to develop drug 
delivery platforms capable of targeting the delivery of anticancer agents to cancerous 
colonic cells. 
 
1.1.1 Colon cancer 
Anatomically, the colon, also known as the large intestine or large bowel, is part of 
the intestine that extends from the cecum to the rectum. Colon cancer refers to cancer 
that is located in the colon or rectum, and it is sometimes called “colorectal cancer”. 
In the United States, colon cancer is the third most commonly diagnosed cancer and 
the second leading cause of cancer-related deaths (American Cancer Society. Cancer 
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Facts & Figures, Atlanta, 2008). In Asia, colon cancer is also the third commonest 
cancer disease, but its incidences in many Asian countries are rapidly increasing 
(Sung, 2007). In Singapore, colon cancer has overtaken lung cancer as the commonest 
cancer and is the second commonest cause of cancer-related deaths 
(http://www.nccs.com.sg/pat/08_03.htm, Jan. 2008).  
 
Cancer is caused by the uncontrolled growth and spread of abnormal cells. Colon 
cancer usually starts as a polyp, which is an overgrowth of normal cells. If the cells in 
a polyp are allowed to grow unchecked, they can become cancerous. Colon cancer is 
highly curable if diagnosed early. The earlier the polyps are discovered and surgically 
removed, the better will be the prognosis. Otherwise, the treatment and prognosis will 
depend on the disease progression at the point of diagnosis. Surgery is often the main 
treatment for early stage colon cancer and it can result in cure in approximately 50% 
of patients (Abraham et al., 2005). However, relapse following surgery is a major 
problem, and is often the cause of death. If surgery reveals that the cancer has spread 
to other organs or tissues, chemotherapy alone or combination with other modalities is 
usually prescribed (Oehler & Ciernik, 2006). 
 
Cancer chemotherapy aims to shrink the tumor size, slow tumor growth and/or reduce 
the likelihood of metastasis developing. In most instances, the primary focus is on 
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killing rapidly dividing cells. Unfortunately, some normal cells also have a high rate 
of division e.g. cells in the bone marrow and hair follicles, and most chemotherapeutic 
delivery systems are unable to differentiate between rapidly dividing cancerous cells 
from other fast proliferating normal cells. Consequently, cancer chemotherapy is often 
associated with serious side effects. To circumvent this drawback, drug delivery 
targeted specifically to colon cancer cells is desired. 
 
1.1.2 Anticancer agents 
The first clinically effective anticancer drug developed was nitrogen mustard, an 
agent initially developed as a war gas. Alkylating drugs based on nitrogen mustard 
were subsequently synthesized and developed for cancer chemotherapy. These drugs, 
like nitrogen mustard, are DNA cross-linkers and they prevent DNA synthesis in cells. 
Many anticancer drugs with different mechanisms of action have since been 
developed (Cavalli et al., 2000), and they include alkylating and intercalating agents, 
as well as topoisomerase inhibitors, which cause direct DNA damage; antimetabolites 
that interfere with DNA synthesis by inhibiting key enzymes in purine or pyrimidine 
synthesis, or by misincorporation into the DNA molecule to cause strand breaks or 
premature chain termination; antibiotic cytotoxic agents that alkylate DNA or inhibit 
topoisomerase II or both; spindle poisons that bind to tubulin to inhibit tubulin 
polymerization or microtubule depolymerization. 
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At the mechanistic level, cellular microtubules-interacting agents are one of the most 
attractive and promising approaches for cancer chemotherapy. Microtubules are 
filamentous polymers that constitute one of the major components of the cytoskeleton. 
They are a superb target because of their important function in mitosis and cell 
division. Table 1.1 shows a list of microtubule-targeted drugs currently in clinical use 
or under clinical development. 
 
Table 1.1 Microtubule-targeted drugs, their binding sites on tubulin, and their stages 
of clinical development (Jordan & Kamath, 2007) 
Binding 
Domain Drugs Therapeutic uses 
Stage of clinical 
development 
Vinca 
Domain Vinblastine (Velban) 
Hodgkin’s disease, 
testicular germ cell cancer 
In clinical use, many 
combination trials in 
progress 
 Vincristine (Oncovin) Leukemia, lymphomas In clinical use, many combination trials 
 Vinorelbine (Navelbine) Solid tumors, lymphomas, lung caner 
In clinical use, many 
clinical trials, Phases I-III, 
single and combination 
 Vinflunine Bladder, non-small cell lung cancer, breast cancer Phase III 
 Cryptophycin 52 Platinum-resistant advanced ovarian caner Phase II 
 Halichondrius (E7389)  Phase II 
 Dolastatins (TZT-1027, Tasidotin) Vascular targeting agents Phase I, II 
 Hemiasterlins (HTI-286)  Phase I 
 
Maytansinoids 
(conjugated to humanized 
monoclonal antibody) 





Mediterranean fever), also 
actinic keratoses 
Appears to have failed 
most cancer trials, 
presumably due to toxicity 
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carcinoid, prostate, breast 
Phase I, II 
 Methoxybenzene-sulfonamide (ABT-751, E7010) 
Solid tumors, 
vascular-disrupting agent Phase I, II 
 Diketopiperazine (NPI-2358) Vascular-disrupting agent Phase I 
Taxane Site 





Ovarian, breast, lung 
tumors, Kaposi’s sarcoma, 
trials with numerous other 
tumors 
In clinical use and in 
combination and single 
drug trials, Phase I-III 
 Docetaxel (Taxotere) Prostate, brain, breast, and lung tumors Phase I-III 
 
Epothilone (Ixabepilone, 
epothilones B (patupilone), 
D, ZK-EPO, KOS-862, 
KOS-1584) 
Taxol-resistant tumors Phases I, II, III 





Estramustine Prostate, often in combination 
Phases I, II, III, in 
combinations with taxanes, 
epothilones, and Vinca 
alkaloids 
 Arsenic trioxide (trisenox) Vascular-disruptive agent  
 Noscapine Leukemia, lymphoma Phase I 
There are two distinct groups of microtubule-interacting agents; the first group 
inhibits the assembly of tubulin heterodimers into microtubule polymers while the 
other stabilizes microtubules under normally destabilizing conditions to prevent their 
disassembly. The latter, of which paclitaxel is a representative compound, will be the 
focus of this project. A variety of natural products have been discovered over the last 
decade to inhibit the proliferation of human cancer cells through a paclitaxel-like 
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mechanism. These compounds represent a whole new set of structurally varied lead 
compounds for anticancer chemotherapy. 
 
1.1.3 Paclitaxel 
Paclitaxel, a diterpenoid derivative, was first discovered at the Research Triangle 
Institute (RTI) in 1967 when Drs. Monroe E. Wall and Mansukh C. Wani isolated the 
compound from the bark of the Pacific yew tree, Taxus brevifolia, and noted its 
antitumor activity in a broad range of rodent tumors. By 1970, the two scientists had 
determined the extremely complex structure of paclitaxel (Hennenfent & Govindan, 
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Since then, paclitaxel has been found to be effective against a wide variety of tumors, 
including refractory ovarian cancer, breast cancer, lung cancer, colon cancer, head 
and neck carcinomas, and acute leukemia (McGuire & Rowinsky, 1995). It works by 
interfering with the normal function of microtubules in cells. Paclitaxel binds 
specifically to the β subunit of tubulin, the "building block" of microtubules (Horwitz, 
1994), and the resultant complex does not have the ability to disassemble. This 
adversely affects cell function because the shortening and lengthening of microtubules 
(termed dynamic instability) is necessary for the transport of other cellular 
components. For example, during mitosis, microtubules position the chromosomes 
during their replication and subsequent separation into the two daughter-cell nuclei 
(Horwitz, 1994; Wang et al., 2005). Consequently, the stabilization of microtubules 
prevents cancer cells from restructuring their cytoskeleton in a flexible manner and 
hinders their aggressive division (Wang et al., 2005). Although normal cells can also 
be adversely affected, cancer cells are far more susceptible to paclitaxel treatment 
because of their much faster rate of cell division. Further research has indicated that 
paclitaxel also induces programmed cell death (apoptosis) in cancer cells by binding 
to a protein called Bcl-2 (B-cell leukemia 2), which is responsible for arresting 
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Despite its effectiveness, paclitaxel is not without disadvantages. One of the major 
clinical problems associated with paclitaxel is its extreme hydrophobicity, and thus 
very low solubility in water (~6-30 mg/ml). The clinical formulation, Taxol®, contains 
paclitaxel (6 mg/ml) dissolved in a 50:50 v/v mixture of the surfactant, Cremophor 
EL® (polyoxyethylated castor oil), and dehydrated ethanol (Straubinger, 1995; 
Hennenfent & Govindan, 2006). Cremophor EL® has been found to contribute to 
serious side-effects, e.g. severe hypersensitivity reactions, and is incompatible with 
common PVC intravenous administration sets. To avoid the hypersensitivity reactions, 
patients have to be pretreated with corticosteroids (e.g. dexamethasone), 
diphenhydramine and H2-receptor antagonist (e.g. cimetidine, ranitidine) before 
Taxol® administration (Singla et al., 2002).  Precipitation of paclitaxel is also an 
issue when the formulation has to be diluted for clinical use (Pfeifer et al., 1993). 
 
Though paclitaxel is a very potent anticancer agent against colon cancer cells, its 
efficacy is limited because of low solubility and poor specificity against cancer cells. 
In order to improve the bioavailability, resolve the intractable solubility and minimize 
the cytotoxicity and adverse side effects associated with paclitaxel therapy, a targeted 
drug delivery system needs to be developed. Many modified formulations and more 
water-soluble analogues of paclitaxel have been investigated (Ibrahim et al., 2002; 
Kim et al., 2004; Soepenberg et al., 2004). Among the methods proposed, 
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nanoparticles of biodegradable polymers are promising in resolving the twin issues of 
the adjuvant problem and the controlled and targeted delivery of the drug (Serpe et al., 
2004; Weissenbock et al., 2004; Musumeci et al., 2006). A nanoparticle formulation 
of paclitaxel bound to albumin (ABI-007) has been approved for the treatment of 
metastatic breast cancer (Gradishar et al., 2005). Paclitaxel incorporated into polymer 
nanoparticles has demonstrated a significant specificity of action mainly because of 
changes in its tissue distribution and pharmacokinetics (Couvreur et al., 1980). These 
changes, directed by the nanoparticle pharmacokinetics, have the potential to improve 
the therapeutic efficacy of paclitaxel with concomitant reduction of its side effects and 
toxicity. In this project, paclitaxel was used as a model drug to develop a nanoparticle 
delivery system with WGA as a targeting moiety with the view to resolve current 
clinical issues associated with paclitaxel therapy. 
 
1.1.4 Targeted delivery of anticancer agents 
Much effort has been expended to improve the selectivity of cancer chemotherapeutic 
agents, and significant improvement in patient survival has been achieved in recent 
years. Nevertheless, the developments of novel selective anticancer agents and new 
ways of delivering both old and new agents are possibly the most important goals of 
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Targeted cancer chemotherapy aims to direct adequate concentration of the chosen 
agent to tumor cells while affecting as few healthy cells as possible. In principle, this 
can be achieved by passive or active targeting. Passive targeting exploits the enhanced 
permeability and retention (EPR) characteristics of tumor vessels. Rapidly growing 
tumors develop extensive vasculatures to meet their requirement for nutrient supply 
and waste disposal, but the blood vessels are abnormally hyper-permeable, with 
defective architecture and impaired lymphatic drainage (Nie et al., 2007). Circulating 
macromolecular drugs or particulate delivery systems that have difficulty permeating 
normal blood vessels can extravasate through such tumor blood vessels, and they 
become entrapped due to the impaired lymphatic drainage in tumor tissues. 
Consequently, the EPR effect can be applied to facilitate the selective accumulation of 
an appropriately designed drug delivery system at a tumor site. To achieve efficient 
accumulation, the delivery system must also avoid systemic clearance by the 
reticuloendothelial system (RES), usually achieved by controlling the size and surface 
properties of the delivery systems (Gref et al., 1994). To avoid RES uptake, a 
hydrophilic surface and small particle size under 100 nm are the most often 
mentioned requirements (Ameller et al., 2003; Owens & Peppas, 2006). Active 
targeting, on the other hand, is often achieved by exploiting the differences in 
membrane biochemistry between cancer and normal cells. Active targeting of a drug 
to cancer cells may involve the conjugation of tissue- or cell-selective ligands 
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(Brannon-Peppas & Blanchette, 2004) that bind specifically with receptors on the 
surface of tumor cells, examples of which include lectin-carbohydrate and 
antibody-antigen interactions (Allen, 2002). Selectivity is ensured by choosing 
ligands that bind to antigens or receptors that are either uniquely expressed or 
over-expressed on the target cells compared to normal tissues. To increase the 
payload to be delivered to the tumor site, the drug may be concentrated in a carrier, 
e.g. nanoparticles, which is then conjugated with the targeting ligand (Fonseca et al., 
2002; Garber, 2004).  
 
Since drug administration routes and the mechanisms of drug delivery are different, 
specific bioconjugates have to be designed according to the delivery pathways and the 
characteristics of the tissues involved. The possibility of targeting drugs specifically 
to the colon has been shown to be feasible (Chourasia & Jain, 2003), and ligands such 
as lectins may have the potential to achieve this goal (Dalla Pellegrina et al., 2005). 
Wheat germ agglutinin (WGA) is an example of plant lectins that binds specifically to 
the N-acetyl-D-glucosamine sugar residues expressed by cancer cells and normal 
gastrointestinal epithelial cells. This specific characteristic may allow WGA to be 
applied as a ligand for targeting drug delivery to colon cells. Moreover, the binding of 
WGA to the gastrointestinal epithelial cells could prolong the retention time, result in 
high local concentration and improve the absorption profile of the drug. Selective 
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binding to cancer cells that expressed the WGA-binding glycoprotein would also 
facilitate the uptake of the WGA-conjugated delivery system into the cells. 
 
The colonic mucosa, like other exposed epithelial surfaces, is covered by a mucus gel 
layer which protects the underlying epithelium against mechanical damage, biological 
agents and chemical irritants. Mucus is a complex mixture of large glycoproteins 
(mucins), water, electrolytes, sloughed epithelial cells, secretory immunoglobulin A 
(Ig A), lysozyme, lactoferrin and α1-antitrypsin (Macfarlane et al., 2005). It forms a 
dynamic viscoelastic gel with high water content (95%) and specific physical 
properties, which allows the gel to flow. An important function of the mucus gel is to 
provide a medium for interaction between the lumen and the mucosal cells, and it has 
been referred to as an “unstirred aqueous layer” (Aksoy & Akinci, 2004). The 
macromolecular glycoprotein component (mucin) is responsible for the viscoelastic 
nature of mucus. In the intestinal mucus, the glycoproteins contain 77.5% of 
carbohydrates which comprise N-acetyl-galactosamine, N-acetyl-glucosamine, 
galactose, fucose and sialic acid at a dry weight molar ratio of 1.0:0.6:0.7:0.3:0.5 
(Moghimi et al., 2001). The high viscosity of mucus can hinder drug diffusion and, 
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Most common malignant tumors of the large intestine are characterized by mucin 
production. The adenocarcinoma, a major colon tumor, forms moderate to 
well-differentiated glands that secrete variable amounts of mucin. The most 
aggressive tumor of the colon, the mucinous carcinoma, is associated with abundant 
mucin secretion (Aksoy & Akinci, 2004), which may impede normal drug delivery to 
the cancer cells. In this respect, mucoadhesive drug delivery systems that bind with 
mucin may prove advantageous, as they could improve contact between drug and 
intestinal cells, as well as prolong the residence time. 
 
1.2 Polymeric nanoparticles 
1.2.1 Nanoparticulate systems for drug delivery 
Nanoparticles are engineered submicron-sized systems that range in size from a few 
nanometers to several hundred nanometers depending on their intended use (Haley & 
Frenkel, 2008). A variety of organic and inorganic materials, including polymers, 
lipids, ceramic and metals, have been used to construct nanoparticles (Yezhelyev et 
al., 2006). Most inorganic nanoparticles have a central core (usually metallic) and a 
protective organic surface coating. Organic nanoparticles include liposomes and other 
lipid-based carriers, polymeric nanoparticles, micelles and various ligand-targeted 
products. Structurally, nanoparticles have also been classified as dendrimers, micelles, 
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nanospheres, nanocapsules, liposomes, fullerenes and nanotubes. Based on their 
manufacturing methods and materials used, the size and shape of nanoparticles vary. 
 
Therapeutic drugs may be incorporated into nanoparticles by surface attachment or 
encapsulation (Haley & Frenkel, 2008). Nanoparticulate drug delivery systems are 
highly versatile. Drug payloads range from small molecular weight drugs to 
macromolecules, from highly water-soluble agents to strongly hydrophobic drugs. 
The method of delivery may vary from the simple, localized delivery using a 
catheter-based approach (Song et al., 1998) to sophisticated targeted delivery whereby 
the conjugation of biospecific ligand onto the nanoparticle surface could direct drug 
delivery to the tissue of interest (Moghimi et al., 2001). In addition, the small particle 
size of nanoparticles yields a high surface area per unit weight ratio that can greatly 
facilitate drug dissolution and absorption in the gastrointestinal fluids. 
Nanoparticulate systems have been demonstrated to improve drug bioavailability (de 
Salamanca et al., 2006), facilitate drug solubilization (Merisko-Liversidge et al., 
2003), sustain drug effect in target tissues (Moghimi et al., 2001) and improve the 
stability of therapeutic agents (Chavanpatil et al., 2006). Since the latter half of the 
1980s, nanoparticles have been studied as carriers for drug delivery to challenge many 
diseases, including cancer, HIV, and diabetes (Yih & Al-Fandi, 2006). Much of the 
research has concentrated on improving the bioavailability of drugs with poor 
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absorption characteristics and providing controlled release of drugs. Table 1.2 gives 
examples of the many different types of nanoparticulate systems currently under 
various stages of clinical investigation (Wang et al., 2008).  
Tabel 1.2 Examples of polymeric nanoparticles in clinical development 
Compound Name Status Indication 
Albumin-paclitaxel Abraxane  or ABI-007 Market Metastatic breast cancer 
Paclitaxel-poliglumex CT-2103; Xyotax Phase III 
Various cancers, particularly 
non-small-cell lung cancer; 
ovarian cancer 
PEG-aspartic acid-doxorubicin micelle NK911 Phase I Pancreatic cancer 
HPMA copolymer-doxorubicin PK1; FCE28068 Phase II Various cancers, particularly lung and breast cancer 
HPMA 





HPMA copolymer-paclitaxel PNU166945 Phase I Various cancers 
HPMA copolymer-camptothecin MAG-CPT Phase I Various cancers 
HPMA copolymer-platinate AP5280 Phase I/II Various cancers 
HPMA copolymer-DACH-Platinate AP5346 Phase I/II Various cancers 
Dextran-doxorubicin AD-70, DOX-OXD Phase I Various cancers 
Modified dextran-camptothecin DE-310 Phase I/II Various cancers 
PEG-camptothecin Prothecan Phase II Various cancers 
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Therapeutic agents of interest are incorporated into polymer nanoparticles either by 
physical entrapment within the polymeric matrix or by surface adsorption or 
conjugation. The size and surface properties of the nanoparticles determine their fate 
in the human body. Unless there is intended drug delivery to the RES, the size and 
surface of the nanoparticles must be designed to avoid RES clearance. Nanoparticles 
smaller than 100 nm in diameter have been found advantageous in this respect 
(Munshi et al., 1997). So is the coating of nanoparticles with the hydrophilic polymer, 
polyethylene glycol (PEG) (Laverman et al., 2001). Targeted drug delivery is realized 
by surface conjugation with a biospecific ligand, which may also favorably modify 
the intracellular disposition of the nanoparticles. Biocompatible, hydrophilic or 
hydrophobic polymer nanoparticles with surface-pendant amine, carboxyl or aldehyde 
groups have been fabricated for further bio-conjugation. A wide variety of ligands, 
such as folic acid (Das et al., 2008), antibody (Natarajan et al., 2008), and aptamers 
(Farokhzad et al., 2004) have been used for surface modification of polymeric 
nanoparticles to impart cancer cell targeting capability. 
 
Polymers employed for nanoparticle fabrication have included synthetic polymers, 
such as Poly (D, L-lactic-co-glycolic acid) (PLGA), polyacrylates and 
polycaprolactones, and natural polymers (Wong et al., 2007). In particular, the 
application of polymer nanoparticles in oncology has grown greatly with the advent of 
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biodegradable polymers (Raghuvanshi et al., 2002; Kreuter et al., 2003). 
Biodegradable polymers are macromolecular materials capable of being degraded into 
simpler products through chemical or enzyme-catalyzed hydrolysis in the body. 
Biodegradable and biocompatible polymers as drug carriers are desirable to minimize 
toxicity and avoid the requirement to surgically remove the spent carriers. For these 
reasons, nanoparticles made of biodegradable materials are often fabricated to provide 
sustained drug release within the target site (Westedt et al., 2007; Yang et al., 2007). 
A good example of a biodegradable and biocompatible polymer is PLGA, an 
FDA-approved biodegradable and biocompatible polymer for biomedical 
applications.  
 
1.2.2 PLGA nanoparticles 
PLGA is a synthetic copolymer of lactic acid and glycolic acid and is one of the most 
widely used FDA-approved biodegradable polymers for controlled release drug 
delivery systems. The biodegradation of PLGA occurs through a hydrolytic chain 
cleavage mechanism. In vivo, PLGA undergoes chemical hydrolysis as well as 
enzymatic cleavage of its backbone ester linkages (Astete & Sabliov, 2006) to form 
the biologically compatible moieties, lactic acid and glycolic acid. The degradation 
products are subsequently eliminated from the body as carbon dioxide and water by 
the tricarboxylic acid cycle (Jalil & Nixon, 1990; Anderson & Shive, 1997). The 
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chemical structure of PLGA is illustrated in Figure 1.2, where “m” and “n” refer to 
the relative amounts of lactide and glycolide units, respectively, in a specific PLGA 
copolymer. The composition of PLGA can be varied by modifying the chain length 
(molecular weight), as well as the ratio of lactic to glycolic acid monomers in the 
polymer chain. This flexibility of composition is advantageous as it can be 
manipulated to yield appropriate physical properties for a particular application. For 
example, the in vivo degradation rate of PLGA can be tailored by controlling the ratio 
of “m” and “n”, with slower degradation rates observed for polymers with higher m/n 
ratios (Lin et al., 2000).  
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PLGA has a long history of safe use as surgical sutures and implants, and it is applied 
in at least 12 different marketed products from 10 different companies worldwide 
(Avgoustakis, 2004). PLGA is used not only as a resorbable suture material and a 
scaffold for tissue engineering, but also in drug delivery (Ignatius & Claes, 1996; Day 
et al., 2005). PLGA delivery platforms have been developed for the sustained and 
targeted delivery of plasmid DNA (Abbas et al., 2008); recombinant HIV envelope 
(env) protein (Moore et al., 1995); hormones (Sun et al., 2008) and anticancer agents 
(Gryparis et al., 2007; McCarron et al., 2008). PLGA nanoparticles have been 
formulated as colloidal carrier systems to improve drug efficacy (Brigger et al., 2002; 
Sahoo et al., 2004; Fukumori & Ichikawa, 2006). Drug release from PLGA 
nanoparticles is controllable through the rate of drug diffusion in the polymer matrix 
and/or degradation of the polymer matrix (Hariharan et al., 2006).  
 
1.2.2.1 Preparation 
Preparation of nanoparticles is frequently based on the use of dispersed systems in 
which solid or liquid phases are dispersed in fluid media to constitute embryos of the 
final particles. Single and multiple emulsion systems have been used to encapsulate 
drugs into polymeric particles. Normally, an organic solvent is required to dissolve 
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the polymers in the emulsion step. To decrease droplet size and avoid droplet 
coalescence, surfactants are usually required. 
 
Techniques for preparing PLGA nanoparticles may be divided into bottom-up and 
top-down approaches. The bottom-up techniques, which include emulsion or 
microemulsion polymerization, interfacial polymerization and precipitation 
polymerization, employ the monomers as a starting point, and nanoparticle fabrication 
occurs simultaneously with monomer polymerization into PLGA. Top-down 
techniques include the emulsion evaporation, emulsion diffusion, solvent 
displacement and salting out methods in which nanoparticles are prepared from 
preformed PLGA (Panyam & Labhasetwar, 2003; Astete & Sabliov, 2006). A good 
review on the characteristics of PLGA nanoparticles prepared by these different 
methods as a function of processing parameters (polymer concentration, co-polymer 
ratio, polymer molecular mass, surfactant concentration, solvent used, phase volume 
ratio) has been published by Astete and Sabliov (Astete & Sabliov, 2006). 
 
Of the techniques reported, emulsion evaporation and emulsion diffusion are the two 
most frequently employed. In the emulsion diffusion method, the PLGA polymer is 
dissolved in an organic phase which is partially miscible in water, and the organic 
phase is emulsified with an aqueous surfactant solution under stirring or sonication. 
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Diffusion of the organic solvent and the counter diffusion of water into the emulsion 
droplets induce polymer nanoparticle formation (Quintanar-Guerrero et al., 1998). 
The emulsion evaporation method is similarly based on emulsification principles, 
except that the organic solvent for dissolving the polymer/drug is highly volatile, and 
is evaporated off following emulsification. Examples of appropriate solvents include 
ethyl acetate, chloroform and methylene chloride. Like the emulsion diffusion method, 
the aqueous phase also contains a dissolved surfactant to impart stability, and 
emulsification is carried out under high-shear stress to reduce the size of the emulsion 
droplet. Important parameters in emulsion evaporation method that may affect 
nanoparticle size are: PLGA co-polymer ratio, polymer concentration, solvent 
characteristics, surfactant/polymer molecular mass, viscosity, phase volume ratios, 
stirring rate, and temperature. Our group has shown that paclitaxel can be 
incorporated at a high loading efficiency into PLGA nanoparticles using a modified 
emulsion solvent evaporation method (Mo & Lim, 2005).  
 
1.2.2.2 Applications 
Biodegradable nanoparticles formulated from PLGA have been widely investigated 
for sustained and targeted delivery of therapeutic agents, including plasmid DNA, 
proteins, and low molecular weight compounds (Panyam & Labhasetwar, 2003; Jiang 
et al., 2005; Sahoo & Labhasetwar, 2005). Encapsulation in PLGA nanoparticles 
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could protect susceptible protein therapeutic agents from physical denaturation and 
chemical degradation, thereby lengthening their half-life. The administration route for 
the proteins can also be changed from injection, which is invasive and associated with 
poor patient compliance, to a more acceptable non-invasive route.  
 
PLGA nanoparticles are also extensively applied for the delivery of anticancer agents 
due to their capacity to enhance drug efficacy by regulating the drug release rate, 
improving drug stability and prolonging drug circulation time in vivo. Incorporation 
of anticancer agents in nanoparticles has been shown to result in a more favorable 
circulation half life, area under the concentration-time curve (AUC) and peak plasma 
concentration (Wang et al., 2004; Kim et al., 2005; Mathot et al., 2006; Lecaroz et al., 
2007). An example is the paclitaxel-loaded PLGA nanoparticles (Vicari et al., 2008), 
which not only reduced the dose and frequency of administration of paclitaxel, but 
also provided improved targeting of the drug to cancer cells. Other anticancer agents 
investigated with PLGA nanoparticles included doxorubicin, camptothecin and 
5-fluorouracil (Betancourt et al., 2007; Li et al., 2008; McCarron et al., 2008). 
Nevertheless, PLGA nanoparticles are not without shortcomings, one of which is their 
non-site specific targeting capability. Another is the rapid removal of the naked 
PLGA nanoparticles from the bloodstream by the RES system. Complete clearance 
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takes only a matter of minutes, with most of the nanoparticle dose concentrating in the 
liver and spleen (Panagi et al., 2001).  
 
Several approaches to improve the selectivity of the delivery system have been 
investigated (Allen, 2002; Nobs et al., 2004; Alexiou et al., 2006), the most common 
of which is the application of nanoparticles conjugated with targeting ligands. Ligand 
conjugation allows the specific delivery of the drug load to cancer cells, which not 
only increases therapeutic efficacy, but also reduces side effects associated with 
non-discriminatory drug deposition. In one study, monoclonal antibody 
(mAb)-modified PLGA nanoparticles (Kocbek et al., 2007) were shown more likely 
to be bound to the targeted invasive epithelial breast tumor cells than non-coated 
nanoparticles. PLGA nanoparticles functionalized with the A10 RNA aptamer (Cheng 
et al., 2007) also resulted in enhanced nanoparticle delivery to the prostate tumor in 
the xenograft mouse model compared to equivalent non-conjugated nanoparticles. In 
yet another study, PLGA nanoparticles conjugated with poly (L-lysine)-poly(ethylene 
glycol)-folate were observed to improve cellular uptake of the nanoparticles into the 
folate receptor over-expressing KB cells by folate receptor-mediated endocytosis 
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A few PLGA-based drug delivery formulations have been in use in the clinic. Lupron 
DepotTM, an injectable suspension formulation of leuprolide acetate-loaded PLGA 
microspheres, is the first peptide formulation for the treatment of advanced prostate 
cancer. Peptide release occurs over a period of 1, 3 or 4 months, and is governed 
mainly by the PLGA degradation rate (Okada et al., 1994; Taluja et al., 2007). 
Nutropin DepotTM is another PLGA microsphere formulation, and it has been 
approved by the FDA in late 1999 for the treatment of pediatric growth hormone 
deficiency (Johnson et al., 1996). Consisting of micronized particles of recombinant 
human growth hormone (rhGH) embedded in a PLGA matrix, this formulation 
requires only one or two doses a month compared to the conventional therapy that 
requires multiple doses per week. There are as yet no PLGA nanoparticle-based drug 
delivery formulations in the market.  
 
1.2.3 Cellular uptake of nanoparticles 
Some anticancer drugs can only exhibit their effects when there is adequate cellular 
uptake either because their receptors are located in the cytosol or their site of action is 
an intracellular organelle. Paclitaxel is one such example. To achieve cytosolic 
delivery, the drug-carrier systems are required to overcome several barriers, which 
include traverse across cell membrane, endosomal uptake and degradation, 
metabolism and efflux transport. To this end, nanoparticles have certain distinct 
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advantages, and paclitaxel-loaded PLGA nanoparticles have been developed recently 
by a few research groups (Mu & Feng, 2003; Wang et al., 2003). Due to their small 
size, nanoparticles can penetrate deep into tissues through fine capillaries, cross the 
fenestration present in the epithelial lining (e.g., liver), and are generally taken up 
efficiently by the cells, which allows for efficient drug accumulation at the target sites 
in the body (Vinogradov et al., 2002). Figure 1.3 depicts a typical intracellular 
trafficking pathway for nanoparticles and other colloidal drug-carrier systems. 
 
Figure 1.3 Schematic drawing of steps involved in cytosolic delivery of therapeutics 
using polymeric nanoparticles (NPs). (1) Cellular association of NPs, (2) 
Internalization of NPs into the cells by endocytosis, (3) Endosomal escape of NPs, (4) 
Release of therapeutic in cytoplasm, (5) Cytosolic transport of therapeutic agent, (6) 
Degradation of drug either in lysosomes or in cytoplasm, (7) Exocytosis of NPs. 
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Generally, two mechanisms are available for the uptake of nanoparticles by absorptive 
epithelia; these are paracellular transport and endocytosis. However, the paracellular 
route is limited by the small surface area of the intercellular spaces and the tight 
junctions between the epithelial cells (Nellans, 1991). Most of the nanoparticle 
formulations are designed to associate with cell membrane and be internalized into 
cells by means of endocytic mechanisms. Endocytosis of nanoparticles depend on the 
physicochemical properties of the particles and the physiological state of the in vivo 
environment (Florence, 2004). Nanoparticles not functionalized with a ligand are 
internalized by cells through adsorptive endocytosis, which is initiated by 
non-specific physical adsorption of the nanoparticles to the cell surface through 
electrostatic forces, hydrogen bonding or hydrophobic interactions (Segretain et al., 
1992). Following endocytosis, the intracellular vesicles would fuse with organelles 
referred to as endosomal compartments. Various types of membrane vesicles have 
been observed to play active roles in endocytosis. Among the various uptake routes, 
receptor-mediated endocytosis (RME) has attracted most attention for the design of 
targeted drug delivery systems as it actively transfers the delivery system into the 
intracellular milieu only when triggered by specific ligand-receptor interaction at the 
cell membrane. Another reason why RME is attractive is that, while nanoparticles 
generally have relatively higher intracellular uptake rates compared to microparticles 
(Desai et al., 1996; Desai et al., 1997), the non-specific cellular uptake of 
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nanoparticles is often not of a high enough capacity to enable cytosolic accumulation 
of therapeutic level of an anticancer drug. This has been an important rate-limiting 
step for the cellular uptake of cationic liposomes in the transfection of Chinese 
hamster ovary (CHO) cells (Hui et al., 1996), and for gene transfer by chitosan 
nanoparticles (Chan et al., 2001). 
 
1.3 Wheat germ agglutinin for drug targeting 
1.3.1 Wheat germ agglutinin 
Lectins are carbohydrate-binding proteins originating from plants, microorganisms or 
animals. They are multivalent molecules with two or more sugar-binding sites that 
can cause agglutination of plant and animal cells, and precipitation of polysaccharides, 
glycoproteins, peptidoglycans and glycolipids. Lectins can recognize and bind with 
specific sugar residues in cell membranes (Rodrigues et al., 2003). The specificity, 
multivalent feature and relatively low immunogenicity of lectins underpin their appeal 
as ligands for developing site-specific nanoparticulate systems for anticancer drug 
delivery. 
Wheat germ agglutinin (WGA) is a lectin purified from the germinating seeds of 
common wheat (Triticum vulgare). It is a 36-kDa protein consisting of two identical 
subunits, each of which comprises of an assembly of four homologous domains 
(Figure 1.4).  
Page 28 
 
Chapter 1 Introduction 
 
 
Figure 1.4 Structure of N-acetylglucosamine–wheat germ agglutinin complex: red, 
N-acetylglucosamine; blue / green, wheat germ agglutinin (Lehr, 2000) 
 
WGA consists of a group of closely related isolectins with an isoelectric point at 
about pH 8.5-9 (Monsigny et al., 1980; Sugawara et al., 2008). The receptor sugar for 
WGA is N-acetyl-D-glucosamine and N-acetyl-D-neuraminic acid residues (Kennedy 
et al., 1995). WGA can bind to oligosaccharides containing terminal 
N-acetyl-D-glucosamine or chitobiose, structures which are common to many serum 
and membrane glycoproteins (Kennedy et al., 1995). Native WGA can also interact 
with some glycoproteins via the sialic acid residues (Monsigny et al., 1979; Monsigny 
et al., 1980). WGA shows preferential binding to the dimers and trimers of sugar (Pan 
et al., 2005). The agglutination between WGA and its receptors occurs very rapidly, 
as disclosed in one study in which all the binding sites available for WGA on the 
Caco-2 cell membrane were occupied within 10 min of incubation (Wirth et al., 2002). 
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WGA does not only bind to cell surface and human enterocytes, but the 
WGA-receptor interaction triggers internalization by the cells by receptor-mediated 
endocytosis (Mo & Lim, 2004). The endocytic process involves the epidermal growth 
factor receptor, which is present at considerable density on enterocytes (Serpe et al., 
2004) (Figure 1.5). 
 
Figure 1.5 Possible pathways for lectin-mediated drug delivery to enterocyte as 
exemplified by WGA (Gabor et al., 2004) 
 
WGA has the potential to be a good ligand for the targeted delivery of anticancer 
drugs to the colon. Lectin affinity chromatography has shown that WGA can bind to 
colon tissue (Serpe et al., 2004).  Compared with plant lectins of different 
carbohydrate specificity, e.g. peanut agglutinin (PNA) and Ulex europaeus 
isoagglutinin I (UEA-I), WGA has the highest binding rate to intestinal cell lines of 
Page 30 
 
Chapter 1 Introduction 
 
human origin, human colonocytes and prostate cancer cells (Gabor et al., 1998). Sugar 
receptors for WGA, the N-acetyl-D-glucosamine and N-acetyl-D-neuraminic acid 
residues, are expressed in the glycocalyx of gastrointestinal cells (Matsuo et al., 1997; 
Khanvilkar et al., 2001), and WGA is rapidly internalized into the cytoplasm of 
human enterocyte-like Caco-2 cells (Gabor et al., 1998). WGA also has relatively 
good resistance to acid pH and enzymatic degradation, and WGA-binding sites are 
ubiquitous along the gastrointestinal tract (Gabor et al., 1997). Moreover, data from 
several studies have demonstrated that WGA-conjugated drugs have improved 
intracellular availability in the colon cells due to a combination of features such as 
cytoadhesion, cytoinvasion and partial lysosomal accumulation (Wirth et al., 1998; 
Gabor et al., 2002).  
 
Colon cancer is often accompanied by alterations in the production of glycoproteins 
on the cell surface (Singhal & Hakomori, 1990). In a study of human colonic mucin, 
Boland et al. confirmed the different expression of carbohydrate residues in 21 colon 
cancer specimens relative to normal tissues (Boland et al., 1982). Another study 
relating lectin-binding patterns in normal and neoplastic colonic mucosa showed 
different patterns for WGA staining in the carcinoma specimens compared with 
normal mucosa (Campo et al., 1988). The aberrant glycosylation patterns expressed 
during malignancy or colitis underscore the attraction of using a lectin-based delivery 
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platform for colon-specific drug delivery. In addition, saturation analysis using the 
fluorescently labeled WGA indicated that the WGA-binding capacity of Caco-2 cells 
was about 13 fold higher than that of normal human colonocytes (Gabor et al., 1997). 
The evidence to date suggests that WGA-mediated drug delivery is a promising 
strategy to overcome the mucosal barrier and possibly the enzymatic barrier for 
colonic drug delivery (Dalla Pellegrina et al., 2005). 
 
1.3.2 Applications 
WGA recognizes both sialic acid and N-acetyl-D-glucosamine, and has been shown to 
transcytose across the small intestinal epithelia into the systemic circulation 
(Giannasca et al., 1994). Specific binding followed by internalization of WGA in 
intestinal and alveolar epithelial cells have been demonstrated by many researchers 
(Ishiguro et al., 1992; Lehr, 2000; Yi et al., 2001). Mucosal immunogenicity studies 
with tomato lectin, WGA, Phaseolus vulgaris (PHA) and Ulex europaeus I (UEA-1), 
showed that WGA is one of the least immunogenic among the lectins studied (Lavelle 
et al., 2000). Cytoadhesion of WGA was followed by immediate endocytosis, with 
30% (monolayer) to 60% (single cell) of the bound WGA internalized within 20 min.  
 
WGA-conjugated colloidal particles have been investigated for their capacity to 
enhance drug targeting and drug uptake by cancer cells. In one study, 
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WGA-conjugated chitosan-Ca-alginate microparticles (MPs) were designed to deliver 
5-FU to colon region (Dodov et al., 2009). The results suggested that 
WGA-conjugated MPs maintained the same sugar specificity as the WGA and 
prolonged residence time in colon. In another study, WGA was covalently attached to 
liposomes through avidin-biotin interaction, giving rise to particles of around 120 nm 
in diameter (Abu-Dahab et al., 2001). The amount of cell-associated WGA-liposomes 
after 30-min incubation with A549 cells was more than 10-fold that of the unmodified 
liposomes. More recently, WGA was covalently conjugated to PLGA microspheres 
by a carbodiimide/N-hydroxysuccinimide method, and the interaction of these 
particles with Caco-2 cell monolayers was investigated using BSA- or 
glycine-conjugated PLGA microspheres as control (Ertl et al., 2000). WGA-PLGA 
nanoparticles were also studied to deliver the model drug, mometasone furoate (MF), 
to A549 cells. The cellular uptake of nanoparticles, intracellular drug levels, and 
anti-proliferative activity were assessed (Surti et al., 2008). Surti et al. (Surti et al., 
2007) also demonstrated an improved and sustained antiproliferative activity obtained 
with the WGA-conjugated nanoparticles in vitro. The same group showed that the 
WGA-conjugated budesonide nanoparticles exhibited better bioavailability when 
administered into the lungs of rats compared to unconjugated nanoparticles (Surti & 
Misra, 2008). WGA-grafted PLGA nanospheres and micospheres have also been 
reported to show enhanced binding and uptake by Caco-2 monolayers (Ertl et al., 
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2000; Weissenboeck et al., 2004). WGA conjugated with doxorubicin has also been 
explored as an acid-labile chemotherapeutic prodrug for targeting against colon 
carcinoma cells (Wirth et al., 1998). Almost all of these studies demonstrated the 
phenomenon of greater cellular uptake of drug and drug delivery systems following 
WGA conjugation. However, the effect of such conjugation on drug retention within 
the colon cancer cells has not been investigated. Moreover, not many of the studies 
have used normal cells as controls when assessing the effects of the the drug delivery 
platforms in colon cell culture. 
 
Our laboratory had demonstrated that WGA-receptor mediated endocytosis 
potentiated the anticancer activity of paclitaxel against A549 and H1299 cell lines 
compared with the conventional formulation, which was attributed to efficient 
intracellular drug accumulation via WGA-receptor-mediated endocytosis (Mo & Lim, 
2004; Mo & Lim, 2005). In vivo study showed that an intratumoral injection of WNP 
at a paclitaxel dose of 10 mg/kg was effective at arresting the growth of A549 tumor 
nodules in the SCID mouse model (Mo & Lim, 2005). To sum up, WGA remains its 
cytoadhesion and cytoinvasion properties after conjugation onto PLGA nanoparticles. 
WGA-PLGA system had superior in vitro and in vivo anti-proliferation activity 
against A549 cells compared with non-conjugated PLGA nanoparticles. On the basis 
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of these results, it may be concluded that WGA-PLGA nanoparticles has significant 
potential application as a targeted delivery system of anti-cancer agents. 
 
1.4 Barriers for intracellular drug delivery 
There are diverse biological barriers interposed between the site of administration and 
the target cell that drugs which act intracellularly must be able to overcome. Effective 
intracellular drug delivery involves the successful traversing of these biological 
barriers, which may involve the modulation of the permeability of relevant biological 
barriers, or the enhancement of the concentration and residence time of the delivery 
systems at the biological barriers. Indiscriminate deposition of the drug at other sites 
must be avoided to limit adverse effects and ensure biocompatibility. If the target cells 
are not readily accessible, adequate systemic absorption of the drug is required to 
ensure therapeutic drug concentrations are reached in the circulation. The absorbed 
drug will then need to be directed to the target cells, where an appropriate residence 
time is required for cellular uptake, preferably in a controlled manner. In the next 
sections, the biological barriers to intracellular drug delivery in the colon will be 
discussed followed by methods employed to enhance the intracellular bioavailability. 
 
1.4.1 Biological barriers 
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There are numerous barriers that can hinder effective drug delivery in the 
gastrointestinal tract. The interplay between digestive fluids and peristalsis can dilute 
and accelerate the transit of drugs and their delivery systems, leading to poor 
absorption. The harsh environment in the gastrointestinal tract can cause drug 
degradation by chemical or enzymatic hydrolyses; and drug access to the absorptive 
cells can be limited by the overlying viscous mucus layer (Shah & Rocca, 2004). 
However, as a site for drug delivery, the colon offers distinct advantages on account 
of a near neutral pH, a much longer transit time, and relatively low proteolytic 
enzyme activity. Systemic bioavailability is also less of a concern for localized drug 
delivery to the colon. 
 
Nevertheless, there are still several challenges to the effective delivery of therapeutic 
agents to the colon. This includes the need to maintain the structural integrity of the 
drug and delivery system during transit to the colon by building in resistance to 
enzymatic and chemical degradation along the GIT. There is also considerable 
resistance to the penetration of the mucosal interface, in particular the mucus layer, 
which is about 25-115 µm thick in the human colon (Matsuo et al., 1997; Strugala et 
al., 2003). The gel-like consistency of the mucus layer is a diffusive barrier, although 
it can also be successfully exploited for drug delivery through the development of 
mucoadhesive formulations. The fixation of a drug delivery system close to the 
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absorption site has been shown to improve the bioavailability of the therapeutic agent. 
At the cellular level, the first barrier encountered by the delivery system is the plasma 
membrane. Even for drugs that managed to enter the cells, the existence of multidrug 
resistance (MDR) efflux pumps in many cancer cells can keep the intracellular drug 
levels below the cell-killing threshold by actively extruding the drugs from the cells. 
Drugs taken up by the cells via endocytosis may have to initiate endo-lysosomal 
escape to avoid degradation. Within the cytosolic milieu, there are microtubules, 
intermediate dilaments and microfilaments that are organized into a dense network to 
form the cytoskeleton (Lechardeur & Lukacs, 2006). These filaments may impede the 
diffusion of the drug or drug delivery system, and will have to be overcome if the 
drug were to reach its target site within the cell. 
 
1.4.2 Strategies to enhance intracellular accumulation 
Although there are diverse mechanisms by which macromolecules and small particles 
can traverse the epithelial layer (Conner & Schmid, 2003), most nanoparticle-based 
drug delivery platforms are designed to gain cellular entry by RME. Thus, they are 
formulated to have an appropriate ligand conjugated on their surface that will aid in 
cellular recognition, binding and internalization. A wide variety of ligands has been 
explored for the targeting of anticancer agents (Ross et al., 1994; Chu et al., 2006; 
Mamot et al., 2006). Alternatively, the nanoparticles may be conjugated with lectin 
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molecules capable of enhancing interaction with the mucus layer. The latter promotes 
nanoparticle transport across the intestinal mucosa by bringing the nanoparticles in 
closer proximity to the surface of epithelial cells (Irache et al., 1994; Clark et al., 
2000). To initiate endosomal escape, the drug may be conjugated to the nanoparticles 
by acid-labile linkages that will hydrolyze in the low pH environment of the 
endosomes (Hoffman et al., 2001; Jones et al., 2003). In this respect, PLGA 
nanoparticles may have an advantage, as they have been reported to successfully cross 
the endosomal barrier to deliver the drug payload into the cytoplasm (Panyam et al., 
2002). Encapsulation within nanoparticles could also be a mechanism to protect 
anticancer drugs from membrane efflux pumps associated with multidrug resistance, 
and exocytosis (Panyam & Labhasetwar, 2003; Park et al., 2006; Ma et al., 2009). 
Reversing MDR phenotypes by colloidal drug carriers or P-gp inhibition by lipids or 
nonionic surfactants used in the formulations were suggested as a possible mechanism 
for the enhanced toxicity in cancer cells (Wong et al., 2006). Nanoparticles localized 
in the cytoplasmic compartment may be slow in diffusing across the cell membrane 
for exocytosis because of the gel-like viscous characteristics of the cytoplasmic fluid 
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1.5 Statement of purpose 
WGA can serve as a specific ligand to actively interact with colon cell membrane 
through RME. PLGA nanoparticles may also play an important role to improve the 
bioavailability of paclitaxel by resolving its intractable solubility profile and 
providing a large surface area for the drug to interact with the biological milieu at the 
absorption site. Moreover, the interaction between WGA and cell membrane or mucus 
can enhance the residence time of the nanoparticles at the absorption site, while the 
presence of intracellular glycocalyx offered further opportunity to retain the 
nanoparticles within the cytosol. 
 
Our objective was to exploit the cytoadhesive and cytoinvasive properties of WGA to 
develop a colon cancer targeted PLGA nanoparticulate system for paclitaxel. PLGA 
have been widely applied as a carrier in drug delivery systems because of its 
biocompatible and biodegradable properties. The nanoparticle formulation was 
preferred because the small size of the nanoparticles might afford evasion from RES 
capture in vivo, while encapsulation of paclitaxel within the nanoparticles allowed 
enhanced drug payload delivery to the target cells. Previous work in our laboratory 
has shown that the surface of PLGA nanoparticles could be readily activated for 
WGA conjugation, and the resultant nanoparticles were effective at delivering 
paclitaxel into lung cancer cells in vitro and in vivo (Mo & Lim, 2005; Mo & Lim, 
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2005). This provided the proof of concept of WGA as a targeting ligand to enhance 
the efficiency of delivery of paclitaxel to cancer cells. Colon cancer is targeted in this 
project because it has been the leading cause of tumor death worldwide, and 
chemotherapy for colon cancer is often associated with serious side effects. Moreover, 
colon cancer with mucin production is often difficult to treat (Nakamori et al., 1994; 
Matsuda et al., 2000).  
 
Mucin is widely expressed in the intestine and in colon cancers. The major component 
of mucin is glycoproteins, which include many WGA-recognizable glycoproteins. 
Nanoparticles can be made to interact with the mucin, a phenomenon known as 
mucoadhesion, by conjugation with WGA. It is generally accepted that mucoadhesive 
polymers will increase drug concentration in the vicinity of the intestinal epithelial 
cells by its close proximity with the intestinal mucosa, and this in turn will enhance 
drug absorption. However, mucin is also an impediment layer to drug delivery as it 
slows down drug diffusion considerably.  
 
The hypothesis for this project was that the conjugation of WGA to PLGA 
nanoparticles loaded with paclitaxel (WNP) could improve the delivery of paclitaxel 
to colonic cancer cells. Paclitaxel has broad antineoplastic activity, including against 
colorectal cancer cells. Its clinical application is however, limited by its poor 
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solubility in aqueous media and its non-specific activity against both cancerous and 
normal cells. Incorporating the drug in a hydrophobic polymer carrier may alleviate 
the solubility issue. PLGA was proposed as the polymer of choice for this purpose 
because of its proven history of use in biomedical applications. Nonetheless, cellular 
uptake of PLGA nanoparticles has been shown to be of low capacity (Chen & Langer, 
1998) and specificity (Kim et al., 2005). Therefore, WGA was proposed as a targeting 
moiety to bind the PLGA nanoparticles to the cancerous colon tissue, and to facilitate 
the uptake of the nanoparticles by the colonic cells via RME. A combination of these 
mechanisms should allow a higher intracellular accumulation of paclitaxel by the 
cancerous cells, thereby realizing the potential of the drug without the attendant side 
effects.  
 
To prove this hypothesis, studies were conducted with the following specific 
objectives: 
1. To screen selected cancer cell models for WGA-binding affinity 
2. To assess the cytotoxicity of WGA against the chosen colon cancer cell 
models 
3. To determine the uptake capacity, cellular paclitaxel accumulation and 
cytotoxicity profile of the WNP on selected colon cancer cell models and 
compare the data with those obtained with the clinical paclitaxel formulation. 
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4. To evaluate the effect of mucin on the intracellular delivery of the WNP by 
repeating the studies in an established mucin-secreting cell model (LS174T). 
5. To evaluate the intracellular trafficking of WNP in the colon cancer cell model 
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2.1 Introduction 
Lectins, including WGA, have become important tools in glycoconjugate research 
because they can be used reliably to detect, isolate and purify specific 
glycoconjugates. Research on the applications of glycoconjugates has been driven by 
a recent explosion of interest in glycobiology, i.e. the biological activities of 
glycoconjugates (Large and Warren 1997), in particular glycoproteins (proteins 
containing covalently bound carbohydrate) that may have therapeutic potential 
(Conradt 1991). Glycosylation is a key step in a number of cellular processes, and 
glycoproteins are ubiquitous constituents of all living cells (Amoresano et al. 2000). 
Carbohydrate-mediated recognition plays a very important role in fertilization, 
immune defence, viral replication, parasitic infection, cell–matrix interaction, 
cell–cell adhesion and enzymatic activity (Komath et al. 2006). Many cancer cells, 
including colon cancer cells, overexpress some kind of glycoproteins, and the 
structural changes in the expression of these molecules contribute to functional 
differences between cancer and normal cells. Cell surface glycosylation changes 
during oncogenesis is further thought to be correlated with malignancy potential 
(Tang et al. 2005).  
 
Lectins, including WGA and some other adhesion molecules, can not only recognize 
specific receptor-like structures of the cell membrane, but may subsequently trigger 
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active transport of the lectin-receptor complex by vesicular transport processes into 
the cell (Lehr 2000). Several previous studies have confirmed the binding of lectin or 
lectin-conjugated drug delivery systems to glycoconjugates on cell surface, followed 
by the facilitated uptake of the systems by the cells (Hussain et al. 1997; Qaddoumi 
and Lee 2004; Ono et al. 2006). On this basis, lectins have been used as targeting 
molecules to localize particular glycoconjugates, such as glycoproteins or glycolipids, 
onto cell surface or intracellular receptors. For example, lectins labeled with 
fluorophore or gold particles are important probes for detecting cell surface 
components and intracellular receptors in immunological and biochemical assay 
procedures (Kimura et al. 1979; Roth 1983). More recently, lectin-conjugated 
trifunctional nanobiosensors have been shown to bind to the surface glycoproteins of 
A549 cells, suggesting their potential application in mapping glycoconjugates on cell 
surfaces (Xie et al. 2008). 
 
In order to use WGA as a tumor-targeting ligand, there is a need to establish the 
expression profile of its receptor glycoproteins in target cells. WGA has a well 
defined and narrow receptor specificity, its receptors comprising of oligosaccharides 
containing terminal N-acetyl-D-glucosamine or sialic acid (Kennedy et al. 1995). 
These structures are common to many serum and membrane glycoproteins (Kennedy 
et al. 1995), making it pertinent to determine whether a WGA-based targeting drug 
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delivery platform is capable of discriminating diseased cells from normal cells. The 
experiments in this section were set out to evaluate whether model colon cancer cells 
over expressed the specific oligosaccharides that would bind the proposed 
WGA-conjugated anticancer drug delivery platform.  
 
Intensified research in glycobiology has led to the development of many new 
techniques for analyzing biological carbohydrate molecules. Some of these techniques 
include 2-Dimensional Nuclear Magnetic Resonance (2-D NMR) and Fast Atom 
Bombardment Mass Spectroscopy (FAB-MS). These methods are indispensable for a 
complete structural analysis of pure glycol molecules, but may not be readily 
accessible because they require expensive equipment and skilled operators. There are 
situations where a less refined analysis that can be performed in a short period of time 
with small amounts of material is sufficient. Other than the above sophisticated 
methods, surface membrane glycoproteins can also be investigated using 
histochemical techniques, while high-resolution electrophoresis is widely used for 
analyzing complex protein mixtures. A combination of these techniques with the 
sensitive biotin-based labeling and biotin-avidin-peroxidase detection system allows 
the rapid analysis of small quantities, ng to about 1 μg, of glycoproteins immobilized 
on membranes. Lectin blot analysis is an example of a glycoprotein analytical method 
that combines histochemical techniques with electrophoresis. 
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For this study, a preliminary comparative electrophoretic study was undertaken using 
lectin blot analysis to investigate the surface and intracellular glycoproteins expressed 
in model colon cells. The 3 colon cell lines evaluated were the Caco-2, HT-29 and 
CCD-18Co cells. Caco-2 cells originate from an old male colon cancer patient. They 
have been the standard in vitro model of intestinal function because they display the 
characteristics of enterocytic differentiation, including the brush border of villus tip 
and tight junctions (Hidalgo et al. 1989). However, Caco-2 cells are also known to 
display a mixed morphology and functionality depending on the passage number of 
the culture (Hidalgo et al. 1989; Jumarie and Malo 1991). HT-29 cells originated from 
a human intestinal adenocarcinoma. They are poorly differentiated but contain a small 
proportion of mucin-secreting cell types which can be selected under certain culture 
conditions, such as in the presence of methotrexate (Lesuffleur et al. 1991; East et al. 
1992). CCD-18Co cells are normal colon fibroblast cells which exhibit most of the 




Caco-2 cells (passage 55-65) were obtained from the Riken Cell Bank (Tsukuba, 
Ibaraki, Japan); HT-29 (passage 140 ) and CCD-18Co cells (passage 7) were obtained 
from the American Type Culture Collection (ATCC; Rockville, MD, USA); tissue 
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flasks and 96-well plates were from NUNC (Roskilde, Denmark); streptomycin, 
penicillin, Hank’s balanced salt solution (HBSS), N-[2-hydroxyethyl] piperazine- 
N´-[2-ethanesulfonic acid] (HEPES), dimethyl sulfoxide (DMSO) and wheat germ 
agglutinin (WGA) were all from the Sigma Chemical Company (St. Louis, MO, 
USA); minimal essential medium (MEM), fetal bovine serum (FBS) and non-essential 
amino acids (NEAA) were from Gibco BRL Life Technology (Grand Island, NY, 
USA); biotinylated-wheat germ agglutinin and Vectastain Elite ABC kit were from 
Vector Laboratory (Burlingame, CA, USA); protease inhibitor was from Roche 
Diagnosis (Basel, Switzerland); polyvinylidene fluoride (PVDF) membrane was from 
Bio-Rad Laboratories Inc (Hercules, CA, USA); Supersignal west pico and west 
femto chemiluminiscence reagent were from Pierce biotechnology Inc (Rockford, IL, 
USA). All the solvents used in the experiments were HPLC grade. 
 
2.3 Methods 
2.3.1 Basic theory of lectin blot analysis 
Western blot, which electronically transfers proteins from a gel to a membrane, is a 
popular method for detecting cellular proteins. By combining the resolving power of 
electrophoresis with the specificity of immunological detection, it can detect a protein 
in a mixture of any number of proteins, and provide information on protein size and 
identity (Rosenberg, 1996). Often, the electrophoretic blots are combined with 
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avidin-biotin methods to provide a more complete interpretation of the glycocalyx 
structural data. Proteins from cells are separated by conventional SDS-PAGE, then 
transferred and immobilized onto suitable membranes for lectin binding. Visualization 
of the bound lectin is provided via biotinylated lectin-avidin binding, in which the 
lectin is tagged with biotin, thus allowing it to bind with a preformed avidin. Avidin 
has such an extraordinarily high affinity for biotin (dissociation constant of about 10-15, 
a million times higher than antibody–antigen affinity) (Green 1975) that the binding of 
avidin to biotin is essentially irreversible. By covalently linking avidin or biotin with 
ligands, such as fluorochromes, enzymes or EM markers, the biotin-avidin system can 
be utilized to study a wide variety of biological structures and processes. This system 
has proven to be particularly useful in the detection and localization of antigens, 
glycoconjugates and nucleic acids by employing biotinylated antibodies, lectins and 
nucleic acid probes, respectively (Milton. 1998). When applied in Western blotting for 
the analysis of glycoproteins by lectins, it is known as a lectin blot. 
 
Gordon and Pena (Gordon and Pena 1982) have discussed the advantages of using 
biotinylated lectins for detecting glycoproteins on membranes. Their method involved 
the preparation of an avidin-biotinyl-peroxidase (ABC) complex which served as the 
protein probe. In this study, we made use of a biotin-conjugated WGA and the 
commercially available ABC complex. The use of avidin-biotinylated WGA has some 
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advantages over the use of 125I-labelled lectins in that it is faster, it gives better 
resolution and it precludes the use of radioactive isotopes (Gordon and Pena 1982). 
Furthermore, the biotinylated WGA is stable on storage over several months and it 
binds to the ABC via specific biotin/avidin interactions, and not to the 
glycocomponents of either avidin or peroxidase (Rohringer and Holden 1985).  
 
Figure 2.1 A diagram depicting the principles of a lectin blot. Biotinylated WGA 
attaches to the membrane glycoprotein of a cell, the biotin label in the WGA is 
amplified with avidin, and the resultant complex is quantified by chemiluminescence 
measurement. 
 
2.3.2 Cell culture 
Caco-2 cells at passages 55-65 were cultured in MEM supplemented with 10% of 
FBS, 1% of NEAA, 100 U/ml of penicillin and 100 µg/ml of streptomycin. HT-29 
and CCD-18Co cells were cultured in McCoy’s 5A and Eagle’s MEM, respectively. 
Cell cultures were incubated at 37°C in a humidified atmosphere of 5% CO2 and 95% 
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air (NuAire US autoflow, NuAire Inc., MN, USA), with medium exchange on 
alternate days. 
 
2.3.3 Whole cell protein and cell membrane protein extraction 
For total cell protein extraction, cells were cultured on 25 cm2 flasks for 3 days. 
Confluent cells were washed thrice with ice-cold PBS and then scraped off into PBS 
with a cell scraper. Cell suspension was transferred into 1.5 ml-eppendorf tubes and 
centrifuged at 3,000 g for 2 min at 4 ˚C (MIKRO 22R, Andreas Hettich GmbH & Co 
KG, Tuttlingen, Germany). The supernatant was discarded and the cell pellet was 
resuspended in lysis buffer (PBS containing 1% of Triton X-100 and protease 
inhibitor according to the instructions by the supplier). After 30 min incubation on ice 
with occasional vortex, the cell lysate was centrifuged at 10,000 g at 4 ˚C for 20 min, 
and aliquots of the supernatant were stored at -80˚C till further use. 
 
Cell membrane protein was extracted using the Mem-PER eukaryotic membrane 
protein extraction reagent kit (Pierce Biotechnology, Rockford, IL, USA) according to 
the manufacturer’s instructions. Traditional methods for isolation of membrane 
protein are tedious, time consuming, and require gradient separation and expensive 
ultracentrifugation equipment (Kashino 2003; Kang et al. 2008; Wang et al. 2008). By 
comparison, the Mem-PER eukaryotic membrane protein extraction reagent kit, 
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which enriches integral membrane proteins from cultured mammalian cells using a 
mild detergent-based protocol [Figure 2.2], provides a faster and easier method to 
isolate membrane proteins. In addition, the isolated membrane (hydrophobic) protein 
fraction can be used directly for SDS-PAGE analysis. 
 
Figure 2.2 Mem-PER reagent protocol [Pierce Biotechnology, Rockford, USA]  
The Mem-PER eukaryotic membrane protein extraction method required the cells to 
be lysed with a detergent, and a second detergent was added to solubilize the 
membrane proteins. After a quick centrifugation, the cocktail was incubated at 37 °C 
to separate the hydrophobic membrane proteins from the hydrophilic proteins through 
phase partitioning. The hydrophilic proteins were assumed to be the intracellular 
proteins excluding the cell membrane protein. The membrane proteins were stored at 
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2.3.4 Protein quantification 
Protein was quantified using the Micro BCA protein assay according to the 
manufacturer’s instructions. It combined the reduction of Cu2+ to Cu1+ by protein in an 
alkaline medium with the highly sensitive and selective colorimetric detection of the 
cuprous cation (Cu1+) by bicinchoninic acid. The principle underlying the assay is 
illustrated as follow: 
 
     1. protein (peptide bonds) + Cu2+                tetradentate-Cu1+ complex 
     2. Cu1+complex + bicinchoninic acid (BCA)          BCA-Cu1+ complex 
A working solution was prepared by mixing 2.5 parts of solution A (sodium carbonate, 
sodium bicarbonate and sodium tartarate in 0.2 N NaOH), 2.4 parts of solution B (4% 
BCA in water) and 0.1 part of solution C (4% cupric sulfate pentahydrate in water). 
The calibration curve was obtained by incubating 100 µl of the working solution with 
100µl of standard BSA solution (concentration ranging from 0.5 to 20 μg/ml) at 37°C 
for 2h, followed by cooling at room temperature for 10 min, and measuring the 
absorbance of the samples at 562 nm (UV-1601 spectrophotometer, Shimadzu Corp. 
Kyoto, Japan). A linear calibration curve was obtained by plotting the sample 





Chapter 2 Screening for WGA-binding glycoprotein in colon cell models 
 
2.3.5 Lectin blot analysis 
A 7.5% polyacrylamide resolving gel and a 4% stacking gel were used according to 
the procedure of Laemmli (Laemmli 1970). Protein samples equivalent to 5 µg of 
protein were size-fractionated by electrophoresis on a 7.5% SDS-PAGE 
(Mini-PROTEAN 3 System, Bio-Rad Laboratories, Hercules, CA, USA) at 150 V for 
1.5 h, and transferred to PVDF membranes, which were blocked by overnight 
incubation in a buffer (TBST) containing 1% of Tween 20, 200 mM of NaCl and 50 
mM of Tris. The membranes were probed with biotinylated WGA for 1 h. After 
washing thrice with TBST, 10 min each time, the membranes were incubated for 1 h 
at room temperature with the avidin-biotin- peroxidase solution from the Vectastain 
reagent kit. The glycoprotein was detected using the west pico chemiluminescence 
system. Bands were visualized in a CCD imaging machine (Fluorchem® HD2, Alpha 
Innotech, San Leandro, CA, USA). 
 
2.4 Results and Discussion  
2.4.1 Protein quantification  
Cell membrane proteins (hydrophobic part) and intracellular proteins (hydrophilic 
part) were quantified using the Micro BCA assay. Cellular protein concentrations in 
the samples were found to be around 0.8-1.5 mg/ml. This concentration was deemed 
adequate for the loading of small volume of protein samples for lectin blot analysis.  
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2.4.2 Lectin blot analysis 
Lectin blot analyses of Caco-2, HT-29 and CCD-18Co cells cultured in 25 cm2 flasks 
showed significant protein bands, confirming the sensitivity of the analysis in 
detecting N-acetyl-D-glucosamine-containing glycoproteins in the cell membrane and 
the intracellular compartment of these cells (Figure 2.3). The objective of this section 
is to obtain a full range of the glycosylation pattern of various colon cancer cells and 
normal cells. However, due to the unavailability of different types of colon cancer 
cells and normal cells, Caco-2, HT-29 and CCD-18Co cells were selected to represent 
colon cell models in our study. Amongst the 3 cell lines, the HT-29 cells showed the 
greatest abundance of WGA-recognizable glycoproteins both in the membrane protein 
sample (Figure 2.3 a) and the intracellular protein sample (Figure 2.3 b). Most of the 
WGA-recognizable glycoproteins in Caco-2 and HT-29 cells had molecular weight > 
75 kDa, whereas the CCD-18Co cells showed an apparent lack of such large proteins. 
The ranking order of expression of WGA-recognizable glycoproteins in the three cell 












        
(a)                         (b) 
Figure 2.3 Lectin blot analysis of (a) cell membrane proteins and (b) intracellular 
proteins in Caco-2 (Lane 1), HT-29 (Lane 2) and CCD-18Co (Lane 3) cells.  
 
These results confirmed the higher expression levels of WGA-binding glycoproteins 
in the human colon cancer cell lines, Caco-2 and HT-29, than in the human colon 
fibroblasts, CCD-18Co, which served as surrogate normal colon cells in this study. 
The existence of N-acetyl-D-glucosamine proteins in both the cell membrane and 
intracellular compartments of these cells would provide promising therapeutic targets 
for WGA-based drug delivery systems. On this basis, we hypothesized that 
WGA-conjugated nanoparticles could be developed to efficiently deliver anticancer 









1     2     3    1     2     3 




proposed that the targeting nanoparticles would not only be internalized, but would 
reside within the cancer cells to allow for an adequate release of anticancer drug to 
kill the cells. 
 
2.5 Conclusion 
Lectin blot analyses confirmed the differential expression levels of 
N-acetyl-D-glucosamine-containing glycoproteins in the cell membrane and 
intracellular compartments of Caco-2, HT-29 and CCD-18Co cells. The ranking order 
of expression of these glycoproteins in the cells was HT-29 > Caco-2 > CCD-18Co, 
suggesting that normal colon cells may express lower WGA-recognizable 
glycoproteins than cancerous colon cells. 
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3.1 Introduction 
The potential utility of cytoadhesive and cytoinvasive wheat germ agglutinin (WGA) 
as a ‘shoehorn’ (Gabor et al., 2002) to improve intracellular uptake of anticancer 
drugs has attracted increasing attention. Aub and his collaborators (Aub et al., 1963) 
first reported that a lipase preparation of wheat germ preferentially interacted with 
tumor specific sites that contained the N-acetyl glucosamine (GlcNAc) moiety. 
Subsequently, WGA was isolated and found to agglutinate leukemia cells (Burger & 
Goldberg, 1967; Kitao et al., 1978). Interest in this cell-agglutinating and 
sugar-specific protein grew when it was found to be a very useful tool for the 
investigation of carbohydrates on cell surfaces, and the separation and 
characterization of glycoproteins (Sharon & Lis, 2004). WGA has many biological 
properties, including its function as recognition molecules in cell-molecule and 
cell-cell interactions, and insight into its action has paved the way for a large number 
of investigations on the use of lectins as tumor diagnostic tools. It is believed that all 
malignant cells share a common property of high lectin-agglutinability that is closely 
correlated with the loss of contact inhibition and tumorigenicity (Rapin & Burger, 
1974). 
 
Lectin-mediated drug delivery relies on the specific interaction between the 
glycocalyx covering the surface of most epithelial cells and the carbohydrate binding 
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site of the lectin ligand. WGA is a dimeric protein characterized by high disulfide and 
glycine contents (Miller & Bowles, 1982; Wright, 1987). It is a lectin with four 
apparently equivalent binding sites that bind specifically to N-acetyl-D-glucosamine 
and N-acetyl-D-neuraminic acid residues on the plasma membrane (Nizheradze, 
2000). WGA has been shown to bind to intestinal cell lines of human origin, e.g. 
human colonocytes, and prostate cancer cells (Zhang et al., 2006). In addition, WGA 
has been observed to rapidly internalize into the cytoplasm of human enterocyte-like 
Caco-2 cells (Dalla Pellegrina et al., 2005). Unlike many proteins, WGA is relatively 
stable to low pH and is able to resist proteolytic attack (Gabor et al., 1997).  
 
The interesting biochemical characteristics aside, WGA is attractive as a targeting 
ligand because it is a protein component of the human diet, being present in wheat 
germ and flour (Dalla Pellegrina et al., 2005, Matucci et al., 2004). Wheat flour 
contains about 300 mg of WGA per kg (Gabor et al., 2004). In cereals, WGA 
concentrations range from 13 to 53 mg/kg (Watzl et al., 2001). While clinical toxicity 
of WGA has not been confirmed conclusively due to a lack of relevant in vivo studies 
(Gabor et al., 2004), the amount of peroral WGA required for optimizing drug 
delivery (nanomolar concentration) is expected to be safe, given that wheat germ 
forms part of the regular diet of man. To date, most toxicity studies of WGA have 
only been recorded in animal or in vitro, with toxicity observed only at very high 
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peroral doses of 7g WGA / kilogram body weight in rats, and even then, only when 
the WGA dose was administered daily over 10 days (Dalla Pellegrina et al., 2005). 
Such doses are significantly higher than the typical dose ingested in a regular human 
diet since the estimated quantity of dietary lectins is in the range 0-200 mg/person per 
d (Watzl et al., 2001). Therefore, within a huge range of concentrations, WGA is 
believed to be non-toxic (Dalla Pellegrina et al., 2005). However, it is worth noting 
that WGA administered to in vitro cell models within the same range of 
concentrations has been shown to be cytotoxic for the human colon cancer cells 
(Pusztai et al., 1993). 
 
WGA has been shown to bind to intestinal cell lines of human origin, with human 
colonocytes exhibiting the highest binding to WGA when compared to other plant 
lectins (Gabor et al., 1997). Our objective was to exploit the cytoadhesive and 
cytoinvasive properties of WGA to develop a colon cancer targeted PLGA 
nanoparticulate system for paclitaxel. To this end, the cytotoxicity and uptake of pure 
WGA to colon cancer cells and normal cells had to be investigated. However, there is 
a scarcity of study comparing the affinities and cytotoxicity of WGA to normal versus 
cancerous colon cell lines. Therefore, the objectives of the study in this section were 
to determine the differential uptake and cytotoxicity of WGA in a variety of human 
colon cell models derived from normal and cancerous tissues. Caco-2, HT-29 and 
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CCD-18Co cells were selected for the experiments. The Caco-2 and HT-29 cell 
monolayers are established in vitro surrogates of the human intestinal epithelium. 
Caco-2 cells spontaneously differentiate into monolayers of polarized enterocyte-like 
cells, connected by tight junctions, that express features characteristic of mature small 
intestinal cells, but they lack mucus-secreting goblet cells (Howell et al., 1992). 
HT-29, an undifferentiated human colon cell line originating from a human colon 
adenocarcinoma, can be modulated in vitro under specific culture conditions to 
control its degree of differentiation and polarization (Le Bivic et al., 1988). They form 
mucus-producing goblet cells under the cultivation medium in the presence of 
methotrexate (Lesuffleur et al., 1993). The third cell line used in the project was 
CCD-18Co cells. These are colonic fibroblasts, and they served as representative of 
normal colon cells. 
 
3.2 Materials 
Wheat germ agglutinin (WGA), FITC-labeled wheat germ agglutinin (fWGA, FITC 
content 2.5 mol/mol lectin), FITC-labeled bovine serum albumin (fBSA, FITC 
content 10 mol/mol albumin), glycine, propidium iodide (PI), DNA-free RNase, SSC 
buffer solution isopropyl myristate (IPM), sodium hydroxide (NaOH), sodium 
dodecyl sulfate (SDS), N-(2-hydroxyethyl) piperazine-N’-(2-ethanesulfonic acid) 
(HEPES), Hank’s balanced salt solution (HBSS), non-essential amino acid, 
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trypsin/EDTA (10×), penicillin G, streptomycin sulfate, sodium bicarbonate, 
3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl tetrazolium bromide (MTT), Eagle MEM, 
dimethyl sulfoxide (DMSO) and trypan blue were products of the Sigma Chemical Co. 
(St. Louis, Missouri, USA). The Micro BCA protein assay kit was purchased from the 
Pierce Co. (Rockford, USA). MEM and McCoy 5A were from Invitrogen (Grand 
Island, NY, USA). Caco-2 cells (human, male colon cancer cell line, passage number 
40) were purchased from the cell bank of the Riken Bioresource Center (Koyadai, 
Tsukuba, Ibaraki, Japan). HT-29 cells (human, female colon cancer cell line, passage 
number 140) and CCD-18Co cells (human colon fibroblast, passage number 7) were 
purchased from the American Type Culture Collection (Virginia, USA). All 
chemicals were of analytical grade. 
 
3.3 Methods 
3.3.1 Cell culture 
Caco-2 cells at passages 50-60 were cultured in MEM supplemented with 10% of 
FBS, 1% of NEAA, 100 U/ml of penicillin and 100 µg/ml of streptomycin. HT-29 
cells were cultured in McCoy’s 5A medium supplemented with 100 U/ml of penicillin, 
100 μg/ml of streptomycin and 10% (v/v) of FBS. CCD-18Co cells were cultured in 
Eagle’s MEM supplemented with 100 U/ml of penicillin, 100 μg/ml of streptomycin 
and 10% (v/v) of FBS. Cell cultures were incubated at 37°C in a humidified 
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atmosphere of 5% CO2 and 95% air (NuAire US autoflow, NuAire Inc., MN, USA), 
with medium exchange on alternate days. Cells were sub-cultured every 3 days after 
trypsinization with trypsin/EDTA solution (0.05 %w/v trypsin; 0.53mM EDTA). 
 
3.3.2 Cytotoxicity of WGA 
In vitro cytotoxicity profile of the WGA was evaluated using the MTT assay. The 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay, first 
described by Mosmann in 1983, is based on the ability of a mitochondrial 
dehydrogenase enzyme from viable cells to cleave the tetrazolium rings of the pale 
yellow MTT to form dark blue formazan crystals (Figure 3.1). Being largely 
impermeable to cell membranes, these crystals would accumulate within healthy cells. 
Solubilization of the cells by the addition of a detergent results in the concomitant 
liberation and solubilization of the formazan crystals, which are quantified by a 
simple colorimetric assay (Scudiero et al., 1988). The number of surviving cells is 
directly proportional to the level of the formazan product created. 
 
Figure 3.1 Biotransformation of MTT to formazan in cells 
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To assess the cytotoxicity of WGA against the Caco-2, HT-29 and CCD-18Co cells, 
the cells were separately seeded onto 96-well plates at a density of 8,000-10,000 
cells/well. When the cells had reached confluence, they were washed with 2 × 200 μl 
of PBS before incubation with 200 μl of WGA solution (10 to 200 µg/ml in respective 
culture medium) for 4 to 72h in the incubator. Cells treated with 0.1% (w/v) of 
aqueous SDS and cells exposed to the culture medium were used as positive and 
negative controls, respectively. After the specified incubation periods, the WGA and 
control solutions were aspirated and the cells were washed thrice with 200 μl of PBS 
followed by incubation with 200 µl of MTT solution (1 mg/ml in PBS) for 3h at 37°C. 
The cells were lysed with 200 µl of DMSO to extract the intracellular purple product, 
and the absorbance of the resultant solutions was measured at 590 nm using a plate 
reader (Spectra Fluor, Tecan Group Ltd, Switzerland). 
 
3.3.3 Protein quantification 
Cell lysate protein was quantified using the Micro BCA assay according to the 
manufacturer’s instructions. The principle underlying the Micro BCA protein assay is 
illustrated as follows:  
 1. Protein (peptide bonds) + Cu2+                 tetradentate-Cu1+ complex 
 2. Cu1+complex + Bicinchoninic Acid (BCA)             BCA-Cu1+ complex  
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This method utilizes bicinchoninic acid (BCA) as the detection reagent for Cu1+, 
which is formed when Cu2+ is reduced by protein in an alkaline environment. A 
purple-colored reaction product is produced by the chelation of two molecules of 
BCA with one cuprous ion (Cu1+). This water-soluble complex exhibits a strong 
absorbance at 562 nm. 
 
3.3.4 Uptake of FITC-WGA (fWGA) 
Caco-2, HT-29 and CCD-18Co cells were separately seeded onto 96-well plates at a 
density of about 1.0×105 cells/ well. Confluent cells on Day 3 were washed twice with 
200 μl of HBSS/HEPES (HBSS buffered with 10 mM of HEPES to pH 7.4), 
pre-incubated with 200 μl of pre-warmed HBSS/HEPES for 1h at 37°C, and 
incubated for 0.5 to 5h at 37°C with 200 μl of 20 μg/ml fWGA solution in 
HBSS/HEPES. Uptake was terminated by washing the cell monolayer twice with 
200µl of HBSS/HEPES. The washed cells were solubilized with 200 μl of 5% SDS in 
0.1M NaOH. Cell-associated fWGA was quantified by measuring the fluorescence of 
the cell lysate in the plate reader (excitation wavelength 485 nm, emission wavelength 
535 nm) and expressed as the uptake amount of WGA (µg) associated with unit 
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3.3.5 Visualization of fWGA cellular uptake  
Laser scanning confocal microscopy (LSCM, also referred to as CSLM, Confocal 
Scanning Laser Microscopy) is an established tool for obtaining high-resolution 
images and 3-D reconstructions of a variety of biological specimens (Matsumoto, 
1993). CLSM allows for a sharp observation of thin optical sections in thick, intact 
specimens. Compared to conventional fluorescence microscopy, confocal microscopy 
has several advantages. The major advantage is its ability to overcome out-of-focus 
reflection. Conventional fluorescence photomicrographs have poor contrast and often 
appear blurred due to fluorescent light scattered around the image, especially 
fluorescence originating from planes other than the plane of focus. Most of the 
unfocused light is excluded in confocal microscopy, which also enables the 
observation of selected thin layers from a thick specimen. As a result, confocal 
images have significantly improved resolution and contrast (Cullander, 1998; 
Robinson, 2001). 
 
Fluorescence microscopy is frequently applied to observe the endocytosis of polymer 
nanoparticles in absorptive cells. However, it is often not easy to discriminate 
between the particles internalized and those externally attached to the cellular 
membrane by observation under the conventional fluorescence microscope. In 1983, 
Sahlin and his colleagues (Sahlin et al., 1983) found that trypan blue (TB, 
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concentration 0.2 mg/ml) at pH 4 could be the most effective of a series of dyes acting 
as a quenching agent for the extracellular fluorescence. The intracellular fluorescence 
was unaffected by TB because the dye was excluded by viable cells. Another study 
showed the internalization of fluorescent polystyrene microparticles by PMN cells 
was successfully differentiated from extracellular particles using the same technique 
(Thiele et al., 2001). In order to differentiate between the membrane-binding and 
internalized fWGA, the TB quenching technique was also used in our study. 
 
Caco-2, HT-29 and CCD-18Co cells were cultured on Lab-Tek chambered cover 
glasses (Nalgene, Nunc International, Naperville, IL, USA) at a seeding density of 1.0 
× 104 cells/cm2 and incubated at 37°C in 95% air/5% CO2 environment. On the 3rd 
day post seeding, cell monolayers were rinsed twice with pre-warmed HBSS/HEPES 
and pre-incubated for 30 min at 37°C with 0.2 ml of HBSS/HEPES before they were 
incubated for 1 h at 37 °C with fWGA solution (20 μg/ml in HBSS/HEPES). Uptake 
was terminated by removing the test or control solution. The cells were washed thrice 
with cold PBS before the extracellular fluorescence was quenched by incubating the 
cells with 0.2 ml of TB solution (0.2 mg/ml in MES, pH 4) for 3 min. The cells were 
then fixed for 10 min in 0.5 ml of acetone/methanol (1:1) at 4 °C. Cell nuclei were 
stained with propidium iodide (2 μg/ml in 2 × SSC containing 25 μg/ml RNase A) for 
10 min at room temperature followed by repeated washings in PBS. The cells were 
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observed under a confocal laser scanning microscope (Zeiss, Heidelberg, Germany) at 
40 × magnifications. 
 
3.3.6 Statistical analysis 
Data were analyzed by one-way ANOVA with the Tukey′s test applied for paired 
comparisons of mean values (SPSS 10.0, SPSS Inc, Chicago, IL). A p value ≤ 0.05 
was considered statistically significant. 
 
3.4 Results 
3.4.1 In vitro cytotoxicity profile of WGA against colon cell lines 
Figure 3.2 shows the in vitro cytotoxicity profiles of WGA against the Caco-2, HT-29 
and CCD-18Co cells. Based on our lab’s experience, the WGA were considered to be 
cytotoxic when they reduced the mean cell viability by 20% or more compared to the 
culture medium control. It was observed that the cell viability for all 3 cell lines 
decreased with increasing WGA loading concentration and exposure time. The 
Caco-2 cells were resistant to ≤10 μg/ml of WGA, even at up to 72h of exposure. 
When the WGA concentration was increased 5 fold to 50 μg/ml, however, the cell 
viability fell below 80% after 24h exposure. By comparison, the HT-29 and 
CCD-18Co cells were resistant to WGA at up to 200 μg/ml as long as the exposure 
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time did not exceed 4h. Prolongation of the co-incubation time to 24h caused these 







































































Figure 3.2 In vitro cytotoxicity profiles of WGA against (A) Caco-2; (B) HT-29 and 
(C) CCD-18Co cells. WGA was applied at loading concentrations of 0.1, 1, 5, 10, 50, 
100 and 200 μg/ml for periods ranging from 4 to 72h. Cell viability determined by 
the MTT assay was expressed as a percent of that obtained for cells exposed to 
culture medium. SDS served as positive control. Data represent mean ± SD, n=6. 
 
3.4.2 Uptake of WGA by colon cell lines 
Uptake of fWGA was studied in the cell lines, Caco-2, HT-29 and CCD-18Co with 
initial fWGA loading concentrations of 5, 10, 20 and 50 µg/ml. The Caco-2 and 
HT-29 cells were representative of colon cancer cells while the CCD-18 Co cells 
served as control normal colon cells. Figure 3.3 shows the results of the uptake studies, 
the fWGA uptake data was expressed as the uptake amount of WGA (µg) associated 
with unit weight (mg) of cellular protein. 
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At all loading concentrations employed, the three colon cell types showed increased 
fWGA uptake with increasing incubation time from 0.5 to 5h. WGA didn’t show 
cytotoxic activity against these cell lines at the test loading concentrations. The 
fWGA uptake profile typically showed a rapid initial uptake rate followed by a slower 
rate of uptake after 30 min. The rank order of fWGA uptake was Caco-2 > HT-29 > 
CCD-18Co cells. Although the Caco-2 cells showed a consistent 1.5 fold higher 
uptake of fWGA compared to HT-29 cells at all time points examined, the HT-29 
cells also exhibited a substantial capacity for WGA binding, the cellular WGA uptake 
reaching about 50% of the initial fWGA load administered to the cells at the loading 







































































































Figure 3.3 Uptake of fWGA by (A) Caco-2, (B) HT-29 and (C) CCD-18Co cells as a 





































































Figure 3.4 Uptake of fWGA by the Caco-2, HT-29 and CCD-18Co cells when 
exposed to fWGA loading concentration of (A) 20 μg/ml and (B) 50 μg/ml (Data 
represent mean ± SD, n=4)  
 
Figure 3.4 is a comparison of the fWGA uptake profiles for the three colon cell lines 
at fWGA loading concentrations of 20 and 50µg/ml. At both concentrations, fWGA 
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uptake by the cell lines was time and concentration-dependent. While all 3 cell lines 
showed rapid initial uptake followed by saturation after about 2h, the effect of fWGA 
loading concentration on the cellular uptake was not the same for the 3 cell types. 
WGA uptake by the Caco-2 cells at the loading concentration of 20 µg/ml was about 
2.5 and 3.0 times higher than those of the HT-29 and CCD-18Co cells, respectively, 
whereas at the 50 µg/ml loading concentration, Caco-2 cells showed 3 fold higher 
WGA binding than the HT-29 cells, whose WGA uptake capacity at this loading 
concentration was comparable to that of the CCD-18Co cells. 
 
3.4.3 Laser scanning confocal photomicrographs 
Confocal imaging of the cells after uptake experiments supported the quantitative data 
generated from the uptake studies. Figures 3.5 showed the confocal images following 
1h uptake of fWGA by the colon cells, which was captured by the combined PI and 
FITC channels. The intensity of the fluorescence (green) was scattered in the cytosol, 
with some fluorescence present in the vicinity of the nuclei (red), indicating that the 
fWGA had been internalized by the cells. Subsequent treatment of the cell 
monolayers with trypan blue, which quenched extracellular fluorescence, did not 
affect the fluorescence intensity observed under the confocal microscope. This 
indicated that the imaged fluorescence was located inside the cells. Moreover, the 
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images were acquired by the sectioning function of CLSM, providing further evidence 
indicating the internalization of the fluorescently labeled WGA. 
Before trypan blue treatment     After trypan blue treatment 
         (a) 
    
 
(b) 
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Figure 3.5 Confocal images of (a) Caco-2, (b) HT-29 and (c) CCD-18Co cells 
incubated for 1 h with 20 µg/ml of FITC-WGA. The images were acquired before and 
after the cells were treated with 0.2 mg/ml of trypan blue post-uptake, which 
quenched extracellular fluorescence.   
 
3.5 Discussion 
For WGA to be applied as a cytoadhesive and cytoinvasive ligand, its binding 
characteristics with target cells has to be evaluated and this can be investigated using 
the fluorescein-labeled derivative. In order to evaluate the selective potential of WGA 
for colon cancer cells, fWGA uptake by the cancerous Caco-2 and HT-29 cells were 
compared in this study to that of CCD-18Co cells, a colon fibroblast chosen to 
represent normal colon cells.  
 
Taken together, the fWGA cellular uptake data supports the hypothesis that 
WGA-binding residues, likely to be N-acetylglucosamine and sialic acid residues or 
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their derivatives (Nizheradze, 2000), were expressed in the glycocalyx of the three 
cell lines, particularly the Caco-2 and HT-29 cell lines. Cellular uptake of fWGA in 
all cases was a concentration- and time-dependent saturable process, the uptake 
efficiency ranking in the order of Caco-2 > HT-29 > CCD-18Co cells. Given the 
insignificant difference in imaged fluorescence following trypan blue treatment of 
exposed cells monolayers, it may be concluded that the measured fluorescence of 
lyzed cells was contributed predominantly by internalized fWGA. Thus, the uptake 
data could be attributable to endocytosed fWGA rather than fWGA adsorbed on the 
cell membrane surface.  
 
Garbor et al. (Gabor et al., 2004) have reported that the intracellular trafficking of free 
fWGA was mediated by clathrin, because the observed decrease in cell-associated 
fluorescence intensity with time at 37°C was indicative of fluorescence quenching in 
an acidic environment, such as lysosomes. Moreover, the decrease in fluorescence 
intensity could be fully compensated by the addition of monensin, an agent that 
reduced the acidity of an intracellular compartment. Published data (Villegas & 
Broadwell, 1993; Mo & Lim, 2004) have suggested that the cellular internalization of 
WGA was mediated by receptor-mediated endocytosis (RME) and adsorptive 
endocytosis (AE), both of which are energy-dependent, saturable processes. RME is 
initiated by ligand binding to specific receptor proteins embedded within the plasma 
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membrane, while ligands are adsorbed onto the cell membrane by non-specific 
interactions in AE (Lehr, 1994). Kramer and his colleagues (Kramer & Canellakis, 
1979) have reported that the binding of WGA to the surface polypeptides of HeLa 
cells induced an extensive endocytosis of both bound and unbound surface 
polypeptides. Raub et al. (Raub et al., 1986) demonstrated that the endocytosis of 
WGA by Chinese hamster ovarian (CHO) cells occurred via invaginated regions of 
both coated and uncoated membranes, with a large fraction of the receptors returning 
to the cell surface at a mean t1/2 of 17 min. Thus, there may be more than one 
mechanism for the uptake of WGA depending on the cell type and the glycoprotein 
expression pattern in the diseased state. In the case of Caco-2 cells, the binding of 
WGA has been attributed to the presence of specific carbohydrate binding sites on the 
cell surface (Gabor et al., 2002), and the internalized WGA has been observed to 
accumulate into lysosomal compartments within 1h (Gabor et al., 2002). 
 
The uptake of WGA by the Caco-2, HT-29 and CCD-18Co cells has been ascribed to 
the simultaneous presence of two phenomena, a linear non-specific uptake and a 
non-linear specific saturable uptake (Brandhonneur et al., 2009). If the specific 
(non-linear) process predominates over the non-specific process, the saturation is 
more apparent, which was the case in our study. This is in agreement with the 
findings of Brandhonneur et al., who reported a higher specific uptake relative to the 
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non-specific uptake for WGA-grafted PLGA microspheres by alveolar macrophages 
(Brandhonneur et al., 2009). In addition, the authors noted that the cellular was 
dependent on the particle-to-cell ratio. Though the adhesion of WGA to the colon 
cancer cells was found to be specific, the affinity of the lectins to the glycocalyx of 
the cells was quite different. The amount of carbohydrate necessary for 50% 
inhibition of WGA-binding to Caco-2 cells was 2 times more than that of HT-29 cells 
(Gabor et al., 1998). Our glycosylation pattern study using SDS-PAGE analyses 
(section 2.4.2) has detected the presence of multiple WGA-reactive glycoproteins in 
the mw bands between 37 and 250 kDa in Caco-2 and HT-29 cells. However, the 
fWGA uptake data are not completely consistent with the cell membrane glycocalyx 
pattern for the Caco-2 and HT-29 cells. Though HT-29 cells express more 
WGA-reactive glycoproteins than Caco-2 cells, the uptake of fWGA by HT-29 cells 
is lower than that of Caco-2 cells. This inconsistence might be due to the different 
analytical method, glycocalyx availability on cell membrane surface, affinity of WGA 
to the cell surface glycoprotein, or the single cell size. 
 
The cellular uptake of fWGA by three cell lines ranked in the order of Caco-2 > 
HT-29 > CCD-18Co. The higher binding of WGA to the malignant cells relative to 
colon fibroblast cells may be associated with the expression of N-acetylglucosamine 
and Sialic acid of the cells. The selectivity of WGA for agglutination with the colon 
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cancer cells relative to the normal fibroblast CCD-18Co cells enable WGA a good 
candidate for formulating a WGA-mediated targeting chemotherapeutic drug delivery 
system for the treatment of colon cancer. 
 
Cytotoxicity of WGA showed a concentration and time-dependence against the 3 cell 
lines studied. WGA was cytotoxic to the three colon cell lines Caco-2, HT-29 and 
CCD-18Co cells at concentrations ≥ 50 µg/ml, particularly upon prolonged exposure. 
Several mechanisms might have accounted for the cytotoxicity of WGA. 
Lectin-dependent macrophage-mediated cell lysis was suggested to be one such 
mechanism (Wang et al., 2000), with the sugar-binding moiety of the lectin molecule 
being partly responsible for anti-cytoproliferative activity. A study by Kim et al. 
showed lectin cytotoxicity to be mediated by soluble lectins that bind to a specific 
receptor that internalized and triggered programmed cell death (apoptosis) (Kim et al., 
1993). Though cytotoxicity of WGA can be advantageous when WGA is directed to 
malignant cells, it could be a source of concern, particularly when the colon 
fibroblasts appeared to be even more susceptible to its deleterious effects. Among the 
three cell lines, the CCD-18Co cells appeared to be the most vulnerable to the 
cytotoxic effects of WGA at higher concentration (≥ 50 µg/ml) and longer incubation 
time. However, this study uses only one fibroblast cell line. The in vivo study showed 
no toxic effect to rats (Dalla Pellegrina et al., 2005). In volunteers consuming wheat 
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germ with equivalent of 200 mg active agglutinin, no side effects were reported 
(Watzl et al., 2001). WGA at concentrations ≥ 50 μg/ml exhibited cytotoxicity to 
varing degrees against cancer and normal cells after long exposure. On the basis of 
these data, the WGA-conjugated PLGA nanoparticles (NPs) should be formulated to 
deliver less than 50 μg/ml of WGA to the cells so as to minimize cytotoxicity, in 
particular to the normal tissues.  
 
While it is possible to control the cellular contact time when the formulation is 
applied to in vitro cell cultures, the cellular contact time will be more difficult to 
control or predict under in vivo conditions. The time taken for food to travel through 
the digestive tract, also known as bowel transit time, can range between 14 to 24h and 
it varies greatly from person to person (Fireman et al., 2005). Thus, it is possible for 
the NPs administered perorally to be retained in the colon for 20h, or even longer in 
view of the bioadhesive property of WGA. Some studies have shown that the binding 
capacity of WGA to cell membranes was affected by food and mucus (Gabor et al., 
2004). This remains debatable because WGA binding to Caco-2 cells was not shown 
to be affected by co-administered wheat flour, starch from potatoes or wheat germ, 
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3.6 Conclusion 
In summary, WGA can mediate cytoadhesion and cytoinvasion of conjugated drug 
delivery carrier to surmount the membrane barrier by temperature-dependent active 
transport mechanisms (Lehr, 2000; Wirth et al., 2002; Weissenbock et al., 2004). The 
conjugation with WGA facilitates cellular uptake, whereas the enzymic barrier might 
be overcome by colloidal formulations or enzyme inhibitors (Gabor et al., 2002). 
Thus, WGA-mediated drug delivery may be a promising strategy to improve the 
availability of poorly permeable drugs. Especially wheat germ agglutinin might 
enhance the uptake of conjugated drugs due to its cytoadhesive and cytoinvasive 
characteristics. 
 
Cellular uptake efficiency of fWGA by the four colon cells ranked in the order of 
Caco-2 > HT-29 > CCD-18Co. WGA showed selectivity for agglutination with the 
malignant colon cancer cells relative to the normal CCD-18Co cells. Therefore, WGA 
may be a suitable ligand for formulating a lectin-mediated targeting chemotherapeutic 
drug delivery system for the treatment of colon cancer. Its cytoadhesive and 
cytoinvasive characteristics provide a promising pathway for improving the binding 
and cellular uptake of anticancer drugs in cancer tissues. WGA at higher concentration 
(≥ 50 μg/ml) exhibited varying degrees of cytotoxicity against both the malignant and 
normal lung cells after prolonged exposure. However, WGA showed no cytotoxicity if 
Page 83 
 




the cells were co-incubated with the WGA at low concentration of 10 μg/ml for up to 
72h. On this basis, the WGA-conjugated drug delivery system should be formulated to 
give tissue exposure to 50 μg/ml or less of WGA so as to minimize cytotoxicity to 
neighboring normal tissues. 
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4.1 Introduction 
The ideal goal of cancer chemotherapy is to destroy cancer cells without harming 
healthy cells. Most anticancer drugs fall short of this ideal. In the case of colon cancer, 
the intravenous delivery of anticancer agents often cause severe side-effects (Kuebler 
et al., 2007). To overcome this drawback, significant efforts have been made to 
develop appropriate targeting systems for colon-specific drug delivery (Patel et al., 
2007; Casadei et al., 2008; Yang, 2008). Among the systems developed, 
nanotechnology-based platforms appear promising in improving therapeutic outcome 
by focusing drug delivery to the target site, and minimizing drug accumulation at 
nonspecific sites (van Vlerken et al., 2007).  
 
Of the nanoparticulate systems reported in the literature, PLGA nanoparticles are 
versatile because they offer a biocompatible vehicle that also present opportunities for 
drug targeting at the cellular level (Mohamed & van der Walle, 2008). PLGA 
nanoparticles can provide sustained drug release and a surface amendable to chemical 
conjugation for targeting purposes, and they bypass the efflux activity of membrane 
transporters (Panyam & Labhasetwar, 2003; Sahoo & Labhasetwar, 2003; Keegan et 
al., 2006; Chen et al., 2008). Previous experiments in our laboratory have shown that 
the conjugation of WGA to PLGA nanoparticles loaded with paclitaxel (WNP 
nanoparticles) could improve the intracellular delivery of paclitaxel to small lung 
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cancer cells relative to lung fibroblasts (Mo & Lim, 2005; Mo & Lim, 2005). The 
purpose of the experiments in this section was to explore the possibility of extending 
the application of WNP to colon cancer chemotherapy. 
 
Paclitaxel is one of the most effective anticancer agents and has a wide spectrum of 
activity against solid tumors, including colorectal cancer (Suffness & Wall, 1995). Its 
clinical application is, however, limited by an intractable insolubility in aqueous 
media and a non-specific activity against both cancerous and normal cells. The 
clinical formulation is Taxol®, which uses a 1:1 v/v mixture of Cremophor EL® and 
ethanol as vehicle (Singla et al., 2002). Several studies have shown Cremophor EL to 
be a problematic vehicle (Trissel et al., 1994; Trissel, 1996). The incorporation of 
paclitaxel into PLGA nanoparticles was promising in resolving the aqueous solubility 
of the drug. However, cellular uptake of PLGA nanoparticles is of low capacity (Chen 
& Langer, 1998) and specificity (Kim & Nie, 2005). To improve the efficiency of 
PLGA nanoparticles as a carrier for intracellular paclitaxel delivery, we 
functionalized the nanoparticle surface with WGA in order to promote their 
internalization and sustained retention by the target cells (Mo & Lim, 2005; Mo & 
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WGA is present at approximately 300 mg/kg in wheat flour (Pusztai et al., 1993). It is 
a 36- kDa protein consisting of two identical subunits, with each subunit comprising 
an assembly of four homologous domains (Lehr, 2000). WGA can specifically 
recognize and bind rapidly with N-acetylglucosamine and sialic acid residues on cell 
membrane, which  leads to cellular internalization through receptor-mediated 
endocytosis (Caldero et al., 1989). Histochemical studies have shown WGA to have 
the highest binding rate to human colonic carcinomas, as well as normal human 
colonocytes, compared with other plant lectins, e.g. peanut agglutinin (Campo et al., 
1988; Caldero et al., 1989; Heinrich et al., 2005). Experiments reported in Chapter 3 
have further confirmed that fWGA was taken up by colon cells in the rank order of 
Caco-2 > HT-29 > CCD-18Co, suggesting that WGA showed agglutination selectivity 
for malignant colon cells relative to the normal colon cells. However, it is not known 
whether WGA upon conjugation to PLGA nanoparticles would retain the capability to 
participate in receptor-mediated endocytosis in the colon cells, which would be 
critical in providing a conduit for the intracellular accumulation of paclitaxel. 
 
The experiments in this chapter aimed to evaluate the differential uptake and efficacy 
of WNP in appropriate colon cell models. The nanoparticles were prepared according 
to the method developed in our laboratory (Mo & Lim, 2005). Cellular uptake of 
WNP by the colon cancer cell lines, Caco-2 and HT-29, and colon fibroblast cell line, 
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CCD-18Co, was quantified by a fluorometric method through the use of fWGA to 
prepare the nanoparticles. The uptake data were correlated with cytotoxicity data of 
the formulation versus control formulations against the cell lines. In addition, we 
attempt to provide an understanding of the mechanism(s) of action of the formulations 
by monitoring paclitaxel-mediated apoptosis using flow cytometry, cell nuclei 
staining and microscopic examination. 
 
WGA-conjugated, paclitaxel-loaded PLGA nanoparticles are designated as WNP, 
while the corresponding fWGA-conjugated nanoparticles are designated as fWNP. 
Control formulations consisted of (a) paclitaxel-loaded PLGA nanoparticles without 
WGA conjugation (PNP), (b) equivalent Taxol® formulation of paclitaxel dissolved 
in a 1:1 solvent mxture of Cremophor EL and ethanol at 6 mg/ml (P/CreEL), and (c) 
drug-free nanoparticles conjugated with WGA (WN), fWGA (fWN) and fBSA (fBN). 
 
4.2 Materials 
Resomer® RG 502H (lactide:glycolide = 50:50, acid number of 10.7 mg KOH/g) was 
a kind gift from Boehringer Ingelheim, Germany. FITC-labeled bovine serum 
albumin (fBSA, FITC content 10mol/mol albumin), 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDAC), 2-(N- 
morpholino)ethanesulfonic acid (MES), N-hydroxysuccinimide (NHS), glucose, 
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phosphotungstic acid (PTA), polyvinyl alcohol (PVA, mw 30,000 – 70,000), glycine 
and isopropyl myristate (IPM) were products of the Sigma Chemical Co.(St. Louis, 
Missouri, USA). Hoechst 33342 (trihydrochloride trihydrate) was purchased from 
Molecular Probes, UK. Paclitaxel (microcrystalline powder, >99.5% purity) was 
purchased from the 21CEC Company (Oaklands, UK) while MEM and McCoy 5A 
were from Invitrogen (Grand island, NY, USA). DNA-free RNase was from the 
Sigma Chemical Company; cell culture dish (100 mm) was from BD Biosciences 
(Falcon, NJ, USA). All other materials are the same as those listed in section 3.2. 
 
4.3 Methods 
4.3.1 Preparation of WGA-conjugated, paclitaxel-loaded PLGA nanoparticles 
PLGA nanoparticles with and without the incorporation of paclitaxel were 
manufactured according to the method developed in our laboratory (Mo & Lim, 2005). 
This method was based on a modified emulsion solvent evaporation method (MESE) 
established for the preparation of PLGA nanoparticles (Murakami et al., 1999; Mo & 
Lim, 2005). Nanoparticles were prepared at ambient temperatures. PLGA (100 mg), 
IPM (30 mg) and, if required, paclitaxel (10 mg), were dissolved in 5 ml of methylene 
chloride. The organic phase was emulsified in 50 ml of aqueous surfactant solution 
(0.5 % (w/v) of PVA) by probe sonication (Sonics VC-130, Sonics and Materials Inc., 
CT, USA, 25 watts output, 2 min, pulse 2 s) on an ice bath, and further magnetically 
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agitated at 1,000 rpm (Thermolyne, Iowa, USA) for 5h to completely remove the 
organic solvent (Scheme 1). 
  
PLGA (100mg), IPM (30mg), Paclitaxel (10mg) dissolved in 5ml methylene 
chloride 
                                 ↓ probe sonication, 2 min 
0.5%PVA solution on an ice bath 
                                  ↓ 
Resultant NP dispersion was stirred at 1000 rpm for 5h to remove the organic 
solvent 
                                  ↓ 
NPs were washed with 4 x 50 ml of distilled water 
                                  ↓ 
Dispersion was concentrated to 10 ml by crossflow filtration using MES buffer, pH 
5.8 
Scheme 1: Schematic diagram on the preparation of PLGA nanoparticles (NP) loaded 
with paclitaxel. 
 
WGA was conjugated to the surface of the PLGA nanoparticles by a two-step EDAC 
method. This method involves the activation of the free carboxyl groups on the 
particle surface in an EDAC/NHS aqueous mixture, followed by conjugation of the 
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activated groups with the amino groups in the lectin molecules. A schematic 
representation of the synthetic pathway is provided in Figure 4.1. 
 
Figure 4.1 Activation of PLGA surface carboxyl groups by 1-ethyl-3- 
(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC) for subsequent surface 
conjugation with WGA 
 
To conjugate the surface of the PLGA nanoparticles with WGA, hardened 
nanoparticles were washed with 4 × 50 ml of distilled water followed by 50 ml of 
MES buffer (0.11M, pH 5.8) in a crossflow cassette (Vivascience, Hanover, Germany; 
molecular cutoff 100,000). The dispersion was concentrated to 10 ml in the cassette 
and then mixed with 1 ml of 0.1M EDAC/0.7M NHS at 100 rpm for 1h at room 
temperature. Excess reaction medium was removed by crossflow filtration and the 
nanoparticles were washed with 3 × 50 ml of PBS. The nanoparticle dispersion was 
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added dropwise into a centrifuge tube containing 2 ml of WGA (1 mg/ml in PBS) 
under vortexing. The reaction was allowed to proceed overnight and unreacted WGA 
was separated from the nanoparticles by crossflow filtration with 3 × 50 ml of PBS. 
Excess coupling sites were blocked by incubating the nanoparticle dispersion (10 ml) 
with 1 ml of glycine solution (200 mg/ml in PBS) for 0.5h at ambient conditions. The 
preparation procedure is summarized in Scheme 2. Preparation of corresponding 
fWGA- and fBSA-conjugated PLGA nanoparticles followed similar procedures 
except that equivalent concentrations of fWGA and fBSA were used in place of 
WGA. 
 
10 ml PLGA nanoparticle suspension 
                        ↓ under stirring speed of 100 rpm 
Incubated with 1 ml of 0.1 M EDAC/0.07M NHS for 1h 
↓ 
Excess reagents removed by washing with 3×10ml PBS using crossflow filtration and             
dispersion was concentrated to 10 ml 
↓ 
Incubated overnight with 2 ml of WGA (1 mg/ml in PBS)  
↓ 
Unbound WGA removed by crossflow filtration with 3×50 ml of PBS 
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↓ 
Incubated for 0.5 h with 1 ml of glycine solution (200 mg/ml in PBS)  
↓ 
Excess glycine removed by cross-flow filtration with 3 × 20 ml of HBSS 
↓ 
Nanoparticle dispersion concentrated to 10 ml and used immediately for analysis. 
 
Scheme 2: Schematic diagram for the conjugation of WGA onto preformed PLGA 
NP. 
 
4.3.2 Characterization of nanoparticles 
4.3.2.1 Particle size, zeta potential and morphology 
Particle size of PLGA nanoparticles was determined with a particle size analyzer 
based on the Photon Correlation Spectroscopy (PCS) principle (Zetasizer 3000HSA, 
Malvern Instruments Ltd., Worcestershire, England). The nanoparticle samples were 
diluted 1:10 (v/v) with deionized water before they were measured for mean size. The 
zeta potential of the PLGA nanoparticle dispersions was determined using the same 
particle size analyzer (Zetasizer 3000HSA). Nanoparticle dispersions were also 
diluted 1:10 v/v with distilled water before they were measured for zeta potential at an 
applied electric field of 150 V. The morphology of the nanoparticles was observed 
under a transmission electron microscope (TEM, Jeol Electron Microscope, 
Page 94 
 
Chapter 4 Evaluation of anticancer activity of WNP 
 
JEM-100CXII, Japan) and scanning electron microscopy (SEM, Hitachi S-4200, 
Japan). For TEM analysis, freshly prepared nanoparticle dispersion were placed on a 
copper grid with Formvar® films and stained with 1% w/v phosphotungstic acid (PTA) 
solution at room temperature for 1 min. Excess staining solution was removed with a 
blotting paper and the nanoparticles were air-dried before they were viewed under the 
TEM. For the SEM study, a drop of nanoparticle suspension was placed on a copper 
grid, air-dried, then mounted onto aluminium sample studs using double-sided carbon 
tapes and Au sputtered at 50 mA for 60 s. The nanoparticles were then viewed under a 
Hitachi S4200 Field Emission Scanning Electron Microscope at 5 kV.  
 
4.3.2.2 WGA loading efficiency 
To quantify the conjugated WGA, a co-solvent system that could dissolve both the 
particle and the protein was used. Lyophilized nanoparticles (FD3 Freezer drier, 
Dynavac engineering Pte Ltd., Wendouree, Australia) were accurately weighed out (5 
mg) and the pellet was dissolved in 0.5 ml of DMSO. After about 1h incubation with 
the occasional manual agitation, 2.5 ml of a 0.05 N NaOH solution containing 0.5% 
w/v SDS was mixed gently. After about 3h, the sample was analysed for protein 
content using the Micro BCA protein assay. Protein-free blank PLGA nanoparticles 
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4.3.2.3 Determination of paclitaxel loading efficiency 
To determine the paclitaxel loading efficiency, 3 mg of lyophilized nanoparticles were 
accurately weighed out and dissolved in 20 ml of a mixture of acetonitrile/water 50:50 
(v/v) aided by bath sonication. 20 µl of the solution was analyzed by HPLC method. 
The HPLC method was developed and validated for the quantitation of paclitaxel. 
Chromatographic separation was achieved on an Agilent 1100 system (Agilent 
Technologies, Palo Alto, CA) equipped with a C18 column (200× 4.6 mm, 5 µm) 
(Waters, Milford, MA) preceded by a guard column (Waters). Flow rate of 1 ml/min 
was applied, with UV detection at 229 nm. The mobile phase consisted of 1:1 v/v 
acetonitrile and water. A linear standard curve was obtained over the concentration 
range of 0.1 to 10 µg/ml (R2 > 0.99). Drug loading efficiency was calculated as the 
weight of paclitaxel relative to the weight of nanoparticles recovered following the 
lyophilization of the nanoparticles. 
                     Weight of paclitaxel recovered in the nanoparticles              
Loading efficiency =  
                              Weight of nanoparticles 
 
4.3.2.4 In vitro drug release 
The in vitro paclitaxel release profile of WNP was determined by measuring the 
residual paclitaxel in the particles after incubation with the release medium (PBS, pH 
7.4) for specified time periods. Freshly prepared nanoparticle dispersion (0.3 ml) was 
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incubated with 30 ml of PBS at 37 ± 0.5 °C in centrifuge tube and shaken horizontally 
at 100 rpm (Shaker bath, Lab Line Instruments Inc., Illinois, USA). At predetermined 
time intervals, three tubes were taken out and centrifuged at 24,000 rpm, 4°C for 20 
min. The pellet was freeze-dried overnight and re-dissolved in 20 ml of mobile phase. 
Paclitaxel content was determined by HPLC (method described in section 4.3.2.3). 
The amount of drug released into the medium was calculated by calculating the 
difference between the residual drug in the pellet and the initial drug load in the 
nanoparticles.  
 
4.3.3 In vitro cytotoxicity of blank WGA-conjugated PLGA nanoparticles (WN) 
In vitro cytotoxicity profile of WN against Caco-2, HT-29 and CCD-18Co cells was 
evaluated using the MTT assay. The cells were separately seeded onto 96-well plates 
at a density of 10,000 cells/well. Nanoparticle dispersions were prepared according to 
the procedures in section 4.3.1. The dispersions were diluted with culture medium to 
0.1 to 5 mg/ml before administration to the cells at 200 μl/well. Upon reaching 
confluency, the cells were washed with 2 × 200 μl of PBS before incubation with 200 
μl of nanoparticle dispersion for 24 or 72 h. Cells treated with 0.1% (w/v) of aqueous 
SDS and 1% aqueous dextran served as positive and negative controls, respectively. 
At the end of the specified incubation periods, the samples were aspirated and the 
cells were washed thrice with 200 μl of PBS followed by incubation with 200 µl of 
Page 97 
 
Chapter 4 Evaluation of anticancer activity of WNP 
 
MTT solution (1 mg/ml in PBS) for 4h at 37°C. The cells were lysed with 200 µl of 
DMSO to extract the intracellular purple formazan, which was quantified by 
measuring the absorbance of the resultant solution at 590 nm using a plate reader 
(Spectra Fluor, Tecan Group Ltd, Switzerland). 
 
4.3.4 Uptake of blank fWGA (fWN) and fBSA- (fBN) conjugated PLGA 
nanoparticles 
To quantify the uptake of fWN and fBN by the three cell lines, the respective cells 
were seeded onto 24-well plates at a density of 1.0 × 105 cells/well. Confluent cells 
were washed and pre-incubated with 200 μl of HBSS/HEPES for 1h at 37°C, then 
incubated for 0.5 to 3 h at 37°C with 0.4 ml of the respective nanoparticle dispersion 
(0.625, 1.25, 2.5, 3.33 or 5.0 mg/ml in HBSS/HEPES). Uptake was terminated by 
washing the cell monolayers twice with HBSS/HEPES and solubilizing the cells with 
0.4 ml of 5% SDS in 0.1M NaOH. Cell-associated fWN and fBN were quantified by 
analyzing the fluorescence intensity of the cell lysates in the plate reader. 
 
The plate reader was calibrated in the following manner. Cultured cells from the 
respective cell lines were harvested from the 24-well plates and lyzed in 0.1 M NaOH 
/ 5% SDS to a final concentration of 5 × 105 cells/ml. Freshly prepared fWN and fBN 
dispersions were diluted in the cell lysate to give final concentrations ranging from 
Page 98 
 
Chapter 4 Evaluation of anticancer activity of WNP 
 
0.625 to 5.0 mg/ml, and the fluorescence intensity of the standard solutions were 
measured in the plate reader.  
 
4.3.5 Antiproliferation activity of paclitaxel 
The in vitro anticancer efficacy of a chemotherapeutic drug can be determined by its 
ability to inhibit the growth of tumor cells, also known as antiproliferation activity 
(Chang et al., 2003; Kanzawa et al., 2003). The MTT assay was used to investigate 
the anti-cytoproliferative activity of paclitaxel against the Caco-2, HT-29 and 
CCD-18Co cells. Cells were cultured on 96-well plates at a seeding density of 8 × 103 
to 10× 103 cells/well in 200 µl of cell culture medium. Cells were cultured for 24 h in 
5% CO2/95% air at 37°C to allow for attachment before they were washed with 3 × 
200 μl of sterile PBS followed by incubation with the paclitaxel solutions (10 to 1000 
nM). The paclitaxel solutions were prepared by serially diluting a paclitaxel stock 
solution (1 μM in sterile DMSO) with cell culture medium. Medium containing 0.1% 
SDS was used as positive control and medium supplemented with 0.5% DMSO and 
1% dextran was used as negative control. The cells were incubated for a further 4, 24, 
48 and 72 h at 37°C before the paclitaxel was removed and the cells incubated with 
100 µl of MTT solution (1 mg/ml in HBSS-HEPES, pH 7.4) for 4 h at 37°C. 
Intracellular formazan crystals were extracted into 100 µl of DMSO, and quantified 
by measuring the absorbance of the cell lysate at 590 nm (Spectra Fluor plate reader, 
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Tecan, Austria) with DMSO as blank (n=6). Cell viability was calculated as a percent 
based on the absorbance measured relative to the absorbance obtained from cells 
exposed only to the culture medium containing 0.5% DMSO. 
 
Parallel experiments were conducted with paclitaxel-loaded formulations against the 
Caco-2, HT-29, and CCD-18Co cells. The cells were plated at 5,000-8,000 cells per 
well, cultured for 24 h to allow for attachment and exposed to WNP, PNP and 
P/CreEL diluted to specified paclitaxel doses with supplemented culture medium. 
Treatment with serum-supplemented medium was used as a negative control (0% cell 
death), and treatment with 0.1% SDS was used as a positive control (100 % cell 
death). 
 
4.3.6 Cellular accumulation and efflux of paclitaxel 
Caco-2, HT-29 and CCD-18co cells were seeded onto 12-mm dishes at a density of 
2×104 cells/cm2 and used after 3 days of culture in 10 ml of respective culture 
medium when they had reached confluency. Cellular uptake experiments were 
initiated by the addition of fresh culture medium containing WNP, PNP or P/CreEL to 
give final concentration equivalent paclitaxel concentration of 40 µg/ml. After 2h 
incubation at 37 ˚C, cells were immediately washed thrice with ice-cold PBS, 
harvested with a rubber scraper, centrifuged at 10,000g for 10 min, and the cell pellets 
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were lysed in 300 µl of methanol under sonication. Paclitaxel content in the 
supernatant was quantified under the chromatographic conditions described in section 
4.3.2.3. The extraction recovery of paclitaxel was determined by comparing peak 
areas of extracts to those obtained on direct injection onto the column of the same 
amount of paclitaxel in methanol. More than 85% of the paclitaxel was extracted into 
the supernatant from cell lysis samples spiked with a known amount of paclitaxel by 
HPLC method. Relative standard deviations (RSD) for day-to-day and within-day 
precision for this assay were less than 10%. The HPLC peaks were recorded and 
integrated using the Agilent data analysis software.  
 
To estimate the rate of efflux of cellular paclitaxel, subconfluent cells in 12-mm petri 
dishes were incubated with 6 ml of WNP, PNP and P/CreEL in culture medium for 2 
h as described above. After the tested sample was aspirated and the cells were washed 
with PBS three times, the cells were further incubated with fresh culture medium 
devoid of drug for another 2 h at 37 ˚C. The paclitaxel content of the harvested cells 
was lyzed and the paclitaxel in the cell lysate was determined by HPLC method as 
described above and the data expressed as paclitaxel content (µg) per unit weight (mg) 
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4.3.7 Visualization of cell-associated nanoparticles  
It is often not easy to discriminate between particles internalized by cells and those 
externally attached to the cellular membrane by observation under the conventional 
fluorescence microscope. It is particularly complicated when the particles are 
bioadhesive and cannot be readily removed by simply washing the cells after the 
uptake experiments. The confocal microscope overcomes these shortcomings by 
'optical sectioning', which allows the selective observation of specified thin layers of a 
specimen (Laurent et al., 1994). A series of confocal sections can then be combined to 
give a three-dimensional image of the specimen. In this study, the internalization of 
WNP by the colon cells was visualized under a confocal microscope.  
 
Uptake experiments of fWNP were performed on cell monolayers cultured in 
Lab-Tek® eight-well chambers (Nalge Nunc Inc., Denmark, seeding density of 1.0 × 
105 cells/cm2). Cells were incubated with 200 µl of culture medium over 72 h before 
they were exposed to 100 µl of fWNP (1 mg/ml in HBSS/HEPES) for 1 h. Uptake 
was terminated by aspiring the nanoparticle dispersion followed by thrice washing 
with PBS. To differentiate between extracellular and internalized nanoparticles, the 
cells were incubated post-uptake with 200 µl of trypan blue (TB) solution (0.2 mg/ml 
in MES, pH 4) for 3 min so that any fluorescence attributed to extracellular WNP 
might be quenched. Cell monolayer was then fixed with 200 µl of methanol/acetone 
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(1:1 v/v) at 4°C for 5 min. Excess staining solution was removed by washing with 3 × 
0.4 ml of cold PBS and the cells were preserved with mounting medium for analysis 
(Zeiss, Heidelberg, Germany, λex 488nm, λem 530nm). 
 
To measure the fluorescence of cell lysate before and after TB treatment, Uptake 
experiments of fWNP were performed as described in confocal study. Uptake was 
terminated by aspiration of the test or control samples and the cells were lyzed with 
0.2 ml of 0.1N NaOH/5% SDS for 30 min and the cell-associated fluorescence was 
measured at λex 485nm and λem 535 nm. 
 
4.3.8 Cell morphological and nucleus fragmentation examination 
Caco-2 cells were seeded on 6-well plates at a density of 10,000 cells/well and treated 
with WNP, PNP and P/CreEL formulations adjusted with culture medium to have the 
same paclitaxel concentration of 40 µg/ml on the 3rd day post-seeding. Cells treated 
with culture medium served as control. At predetermined time intervals (4 h and 24 h), 
the cells were washed with cold PBS thrice and cell morphology was examined under 





Chapter 4 Evaluation of anticancer activity of WNP 
 
Caco-2 cells were seeded on 6-well plates at a density of 10,000 cells/well and 
similarly treated with test samples as described in cell morphology study. Following 
the decanting of test sample, the cells were washed with cold PBS three times and 
fixed in 0.4 ml of a methanol: acetone (1:1 v/v) solvent mixture at 4 °C for 10 min. 
The cells were then washed with cold PBS, air-dried and stained with Hoechst 33342 
for 10 min. Excess Hoechst 33342 was removed by washing with cold PBS and 
nucleus images of the cells were acquired under Nikon microscope. 
 
4.3.9 Cell cycle analysis by flow cytometry 
A cell cycle is composed of four phases: G1, the phase in which the cell prepares for 
DNA replication; S phase, in which the DNA is replicated; G2 phase, in which the cell 
pauses as it prepares to divide; and M, the mitotic (dividing) phase. The DNA content 
of a cell can provide information about the cell cycle and, by extension, the effect of 
stimuli on the cell cycle (Sherwood & Schimke, 1995; Terho & Lassila, 2006). 
Propidium iodide can intercalate with DNA so as to allow for the detection and 
quantification of the DNA content when the cells are individually passed through a 
beam emitted from the light source of a flow cytometer (Studzinski, 1995). The use of 
flow cytometry to quantify nuclear DNA stained with propidium iodide (PI) is one of 
the most widely used methods to measure the proportion of cells in different stages of 
the cell cycle. The effectiveness of this method lies in the linear correlation between 
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the amount of nuclear DNA and the fluorescence of PI stained nuclei (Terho & 
Lassila, 2006). In addition, there is no need to synchronize the cells to a specific phase 
since cells can be sorted based on the DNA content (Studzinski, 1995). As paclitaxel 
is known to induce G2/M arrest of the cell cycle by impairing the function of the 
mitotic spindle and other microtubule–containing structures (Wang et al., 2000), flow 
cytometry was used in this study to evaluate the effects of WNP, PNP and P/CreEL 
on the cell cycle distribution of the Caco-2 cells. 
 
Caco-2 cells were seeded onto 75 cm2 culture flasks at 3 × 106 cells/flask with 15 ml 
of culture medium. At 24 h post seeding, the cells were incubated with 10 ml of WNP, 
PNP and P/CreEL formulation (adjusted with HBSS/HEPES to paclitaxel 
concentration of 40 µg/ml) at 37 °C for 5 to 24h. Cells treated with culture medium 
served as control. At the end of the specified incubation period, the test medium was 
collected into a centrifuge tube, and the cells were harvested by trypsinization and 
pooled with respective medium. The cells were then washed twice with 5 ml of PBS, 
fixed by dropwise addition of 4.5 ml of 70% ethanol with vortex mixing to avoid 
aggregation, and stored at -20°C overnight. Ethanol was removed by centrifugation 
(MIKRO 22R, Andreas Hettich GmbH & Co KG, Tuttlingen, Germany) at 1400 g, 
and the cells were washed twice with 5 ml of PBS before staining (0.1% of Triton 
X-100, 20 µg/ml of PI and 200 µg/ml of RNase in PBS, 1 ml) for 30 min at room 
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temperature. The cell cycle distribution of 10,000 cells in each sample was analyzed 
by flow cytometry (Dako Cytomation Cyan  ADP/LX, Fort Collins, CO, USA), and 
the data analyzed using the Summit v4.3 software (Dako Colorado, Inc., USA).  
 
4.3.10 Cellular trafficking of WNP 
One of the key potential advantages of WNP is its capability to traverse biological 
barriers, which will assist in the intracellular delivery of therapeutic molecules. 
Insight into the intracellular translocation of WNP is therefore important in providing 
a measure of its effectiveness as an anticancer drug delivery system. In this study, we 
aimed to monitor the time-dependent transport of fWNP in the cytoplasm of Caco-2 
cells. To this end, Lysotracker Red DND-99 was used to stain the late endosome and 
lysosome, while Hoechst 33342 was used to stain the cell nuclei.  
 
The uptake experiments were performed on cell monolayers cultured in Lab-Tek® 
eight-well chambers. 100 µl of fWNP (1 mg/ml in HBSS/HEPES) were added into 
the chamber and the cells were incubated for further specified time periods from 0.5 
to 3 h. 0.5h before the end of the incubation period, Lysotracker Red DND-99 was 
applied to the incubation medium at a final concentration of 1 µM to stain the acidic 
organelles (e.g., endosomes and lysosomes). Uptake was terminated by removing the 
medium from the chamber. Hoechst 33342 was then applied to each chamber at a 
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final concentration of 20 µM and the cells incubated for a further 10 min to allow for 
nucleus staining. The cells were washed thrice with ice-cold HBSS/HEPES and fixed 
with 100 µl of methanol/acetone (1:1 v/v) at 4°C for 5 min. Cell images from the 
bottom of the chamber to the cell monolayer surface were recorded using the confocal 
microscope (Z-series images), then reconstructed to provide the intracellular 
trafficking pathway of fWNP. Control experiments were performed by exposing the 
cells to 100 µl of WGA (2 mg/ml in HBSS/HEPES) for 1h before the uptake study.  
 
4.3.11 Statistical analysis 
Data are presented as mean ± standard deviation. Differences between mean values 
were analyzed for significance by one-way ANOVA using the SPSS 10.0 software. P 
values ≤ 0.05 were considered to be significantly different. 
 
4.4 Results 
4.4.1 Characterization of WGA-conjugated paclitaxel-loaded PLGA nanoparticles 
4.4.1.1 Particle size, zeta potential and morphology 
As shown previously by our laboratory, and confirmed in this study, the MESE was a 
simple and reproducible method for the preparation of WGA-conjugated 
paclitaxel-loaded PLGA nanoparticles. Following WGA conjugation, the mean 
particle size of the PLGA nanoparticles increased by about 50 nm to 322 ± 5 nm (n 
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= 3), while the binding of positively charged WGA to the carboxylic groups of PLGA 
resulted in a lowering of the zeta potential of the nanoparticles to -3.3 ± 0.2 mV (n 
= 3) (Table 4.1). These results were consistent with those obtained in previous 
experiments conducted by our laboratory (Mo & Lim, 2005). The nanoparticles had a 
narrow size distribution, indicating a relatively homogeneous population, and 
appeared relatively spherical in shape when viewed under the TEM and SEM (Figure 
4.2).The electron micrographs showed no evidence of particle aggregation. 
 
 Size (nm) Zeta potential (mV)
Before WGA conjugation 223 ± 2 -14.9 ± 1.8 
After WGA conjugation 
 
322 ± 5 -3.3 ± 0.2 
Table 4.1 Size and zeta potential of PLGA nanoparticles before and after conjugation 
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                (A)                                 (B) 
Figure 4.2 (A) TEM (magnification 100,000x) and (B) SEM (magnification of 
35,000x) micrographs of WNP 
 
4.4.1.2 WGA loading efficiency 
Calibration of the Micro BCA protein assay with WGA standard solutions yielded the 
following linear equation: absorbance = 0.0388.Conc (μg/ml) + 0.1483 (R2 = 0.9992). 
The WGA conjugation efficiency for the nanoparticles was found to be 18.1 ± 2.5 
μg WGA/mg nanoparticles (n =3), and was within narrow limits between batches. 
The collective data suggest that the WN nanoparticles were reproducible on a batch to 
batch basis. 
 
4.4.1.3 Determination of paclitaxel loading efficiency 
Linear calibration equation of peak area as a function of concentration for paclitaxel 
solutions assayed by HPLC was: Area = 35577 C (μg/ml) + 46960 R2 = 0.9997. The 
presence of all excipients such as PLGA, PVA and IPM had no influence on the 
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retention time and peak area of paclitaxel. The paclitaxel loading efficiency was 
found to be 53.6 ± 1.8 μg paclitaxel / mg nanoparticles. 
 
4.4.1.4 In vitro drug release 
The in vitro release profile of paclitaxel from WNP was showed in Figure 4.3. There 



























Figure 4.3 In vitro release profiles of paclitaxel from WNP into PBS, pH 7.4, 37°C 
(Mean ± SD, n=3) 
 
4.4.2 In vitro cytotoxicity profile of blank WGA-conjugated PLGA nanoparticles 
In vitro cytotoxicity experiments of WN were conducted with culture medium as 
control medium, and 0.1% SDS and 1% dextran as positive and negative controls, 
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respectively (Figure 4.4). Based on the dextran data, the nanoparticles were 
considered to be cytotoxic when they reduced the mean cell viability by 20% or more 
compared to the cell culture medium control. On this basis, the viability of Caco-2 
and HT-29 cells were considered to be unaffected by 24h of incubation with up to 5 
mg/ml of nanoparticle. At the the incubation time of 72h, the viability of these two 
cell types was adversely affected by the nanoparticles at 5 mg/ml. The CCD-18Co 
cells were more sensitive to the WN, exhibiting lower cell viabilities when exposed to 
5 mg/ml of nanoparticles at 24h, and to 2.5 mg/ml of nanoparticles at 72h. Subsequent 
experiments were performed using equivalent WGA-conjugated PLGA nanoparticle 
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Figure 4.4 In vitro cytotoxicity profile of blank WGA-conjugated PLGA 
nanoparticles against colon cells (a) positive and negative control; (b) Caco-2 cells; (c) 
HT-29 cells; (d) CCD-18Co cells (Mean ± SC, n = 6) 
 
4.4.3 Uptake of blank fWGA-conjugated PLGA nanoparticles 
To determine whether the conjugation of WGA to the PLGA nanoparticles would 
compromise its capacity to bind to receptors expressed in cell membranes, uptake 
studies of fWN were conducted in the colon cancer cell lines (Caco-2 and HT-29) and 
normal colon cells (CCD-18Co), fBSA-conjugated PLGA nanoparticles (fBN) served 
as control. The uptake study was conducted over incubation time periods ranging 
from 0.5 to 3h, using nanoparticle loading concentrations ranging from 0.625 to 5 
mg/ml. 
 
As shown in Figures 4.5 and 4.6, the 3 cell lines showed successful uptake of fWN, 
indicating that the conjugated WGA retained its capacity to recognize and bind to 
receptors expressed in the cell membranes. Uptake of the nanoparticles by all 3 cell 
lines was concentration- and time-dependent, the cellular uptake increasing with 
nanoparticle loading concentration and exposure time. At the nanoparticle loading 
concentration of 1.25 mg/ml, the uptake by the Caco-2 cells was increased by 2-fold, 
from 0.57 to 1.29 mg NP/mg protein, by prolonging the incubation time from 0.5 to 
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3h. Uptake of fWN by Caco-2, HT-29 and CCD-18Co cells at 0.5h were 0.57, 0.50 
and 0.26 mg NP/mg protein, respectively. At the fixed incubation time of 2h, an 
8-fold increase in nanoparticle loading concentration resulted in 9.1, 5.2 and 4.8 folds 
increase in the cellular uptake of the nanoparticles by the Caco-2, HT-29 and 
CCD-18Co cells, respectively. At all time points and loading concentrations studied, 
the ranking order of uptake for the WGA-PLGA nanoparticles was Caco-2 > HT-29 > 
CCD-18Co, suggesting a selectivity of the delivery system for colon cancer cells over 
normal cells. This would be advantageous when the system is used to deliver an 
anticancer agent to the colon tissues. Corresponding cellular uptake of fBN by the 3 
cell types is shown in figure 4.7. Compared with fWN, the cellular uptake of fBN was 
of lower capacity in all 3 cell types. Uptake of fWN by the Caco-2 cells was about 12 



























Figure 4.5 Uptake of fWN by Caco-2, HT-29 and CCD-18Co cells as a function of 
incubation time at loading concentration of 1.25 mg/ml (Mean ± SD, n = 3) 
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Figure 4.6 Uptake of fWN as a function of loading concentration by Caco-2, HT-29 


























Figure 4.7 Uptake of fBN as a function of incubation time at loading concentration of 
1.25 mg/ml (Mean ± SD, n = 3) 
 
4.4.4 Antiproliferation activity of paclitaxel 
Viability of all the three colon cell lines after exposure to paclitaxel was found to 
decrease with increasing exposure time and concentration (Figure 4.8), with the 
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HT-29 cells being the most sensitive to the anticancer drug. These results indicate that 













































































Figure 4.8 In vitro cytotoxicity profile of paclitaxel against (a) Caco-2 cells; (b) 
HT-29 cells; (c) CCD-18Co cells (Mean ± SD, n = 6) 
 
4.4.5 Antiproliferative activity of paclitaxel-loaded PLGA nanoparticles 
Figure 4.9 shows the in vitro cytotoxicity profiles of P/CreEL, PNP and WNP against 
the three colon cell lines. Cytotoxicity was evaluated for the paclitaxel concentration 
range of 0.05 to 50 µg/ml, equivalent to nanoparticle concentration of up to 1 mg/ml, 
which had previously been shown (section 4.4.2) to be non-cytotoxic to the cells. The 
nanoparticles were sterilized by gamma-irradiation for 72 h prior to addition to the 
cells.  
 
The Caco-2, HT-29 and CCD-80Co cells exhibited decreased viability in the presence 
of increasing concentrations of nanoparticles and upon prolongation of co-incubation 
time. A comparison of the efficacy of the 3 formulations suggests that WNP was more 
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effective at lowering the cell viability of Caco-2 and HT-29 cells compared to PNP 
and P/CreEL. After 72h of co-incubation, Caco-2 cells had less than 40% viability 
when incubated with 50 µg/ml of WNP (equivalent to a low paclitaxel concentration 
of 2.5 µg/ml) whereas the P/CreEL formulation produced a viability of 70% in these 
cells. Of the 3 cell types, HT-29 cells were the most sensitive to the effects of 
paclitaxel, which was in agreement with the results obtained in section 4.4.4. The 
WNP formulation was able to reduce the viability of HT-29 cells to below 20% after 
co-incubation for 72h at concentrations ≥ 50 µg/ml. In contrast, the CCD-80Co cells 
were least affected by the 3 formulations, although they were still more sensitive to 







































































Figure 4.9 In vitro cytotoxicity profiles of P/CreEL, , PNP and WNP against (a) 
Caco-2 cells; (b) HT-29 cells; (c) CCD-18Co cells as a function of incubation time 











   Cell type 
Caco-2 HT-29 CCD-18Co 
WNP 
24h 1.019±0.233 0.061±0.021* 1.007±0.121* 
72h 0.087±0.020*^ 0.028±0.008*^ 0.137±0.027* 
PNP 
24h 1.141±0.341 0.092±0.030* 1.188±0.170 
72h 0.228±0.031*^ 0.062±0.015^ 0.147±0.035* 
P/CreEL 
24h 1.387±0.158 0.310±0.019 1.665±0.251 
72h 0.355±0.015 0.069±0.013 0.230±0.021 
Table 4.2 IC50 values of paclitaxel formulated as WNP, PNP and P/CreEL. IC50 
values were evaluated after 24 and 72 h exposure and the results represent Mean ± SD 
values (µg/ml) of three independent experiments, each performed in triplicate.  ‘*’ 
indicates statistical significance compared to P/CreEL (p < 0.05), ‘^’ indicates 
statistical significance between the WNP and PNP formulations (p < 0.05). 
 
When the cytotoxicity data were translated into IC50 values, calculated on the basis of 
paclitaxel content (Table 4.2), the WNP and PNP formulations yielded comparable 
IC50 values with the P/CreEL formulation against Caco-2 cells after 24h co-incubation. 
Enhanced cell-killing effects were observed for WNP, however, upon prolongation of 
the incubation time to 72h, whereupon the IC50 value was significantly reduced to 
0.087 ± 0.020 µg/ml. This value was significantly lower than the IC50 values for PNP 
and P/CreEL. Similar results were observed for the HT-29 cells.  
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However, as the HT-29 cells were more sensitive to paclitaxel, the IC50 values for all 
3 formulations were lower for this cell model than for the Caco-2 cells. In addition, 
the WNP and PNP formulations exhibited greater efficacy than the P/CreEL 
formulation at the shorter incubation time of 24h, and there were statistical 
differences between the IC50 values for WNP and PNP (Table 4.2) at both 24 and 72h 
of incubation. WNP and PNP also showed lower IC50 values in the CCD-18Co cells 
compared to the P/CreEL formulation at 24 and 72 h of co-incubation, but there were 
no significant differences in performance between the two nanoparticle formulations 
of paclitaxel in this cell model.  
 
4.4.6 Cellular accumulation and efflux of paclitaxel 
Figure 4.10 shows the data obtained for the cellular accumulation and efflux of 
paclitaxel in the Caco-2, HT-29 and CCD-18 Co cells exposed to the P/CreEL, PNP 
and WNP formulations. After 2h of incubation, the cellular uptake of WNP was about 
1.5 and 2 folds greater than that of PNP in the Caco-2 and HT-29 cells, respectively. 
WNP also demonstrated increased intracellular retention (30% of uptake) in the 
Caco-2 cells, following post-uptake incubation with fresh medium, compared to the 
unconjugated PNP nanoparticles (18%) and the P/CreEL (7%). Similar phenomena 
were observed in the HT-29 cells, which retained more than 40% of the internalized 
WNP and 27 % of PNP.  The CCD-18Co cells, on the other hand, showed similar 
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uptake and post-uptake retention profiles of paclitaxel when exposed to the WNP and 

























































































Figure 4.10 Cellular uptake of paclitaxel after 2h exposure to the WNP, PNP and 
P/CreEL formulations and intracellular retention of paclitaxel following post-uptake 
incubation of the cells with fresh medium (a) Caco-2; (b) HT-29; (c) CCD-18Co cells. 
Data represent mean ± SD, n = 3.  ‘*’ indicates statistical significance compared to 
PNP and P/CreEL (p < 0.05) 
 
4.4.7 Visualization of cell-associated nanoparticles  
To differentiate between extracellular and internalized WNP, we repeated the uptake 
experiments on Caco-2 and HT-29 cells using a WNP formulation prepared with 
fWGA. The cells were incubated post-uptake with trypan blue so that any 
fluorescence attributed to extracellular WNP might be quenched. Figure 4.11 shows 
the confocal microscopic images of the Caco-2 and HT-29 cells before and after 
post-uptake TB incubation. In the 1-h uptake experiment with the fluorescent WNP, 
there were no significant changes in the cell-associated fluorescence after the cells 
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were incubated with TB. Fluorescence of the cell lysate before and after TB treatment 
was also measured. About 96.3% of the WNP retained after TB treatment, indicating 
that the fluorescence seen is caused by the nanoparticles localized inside the cell and 
not on the surface. 
Before TB treatment             after TB treatment 
(a) 
   
        (b) 
   
          
Figure 4.11 Confocal images of (a) Caco-2; (b) HT-29 cells incubated with 1.0 mg/ml 
of fluorescent WNP for 1hbefore and after TB treatment. 
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4.4.8 Cell morphology 
Control 
 
4h                             24h 
WNP                                           
     
PNP 
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Figure 4.12 Cell morphology of Caco-2 cells after incubation with WNP, PNP and 
P/CreEL formulations for 4 and 24h at equivalent paclitaxel concentration of 40 
µg/ml. 
 
The microscopic images of Caco-2 cells after treatment with WNP, PNP and P/CreEL 
for 4 and 24 h are shown in Figure 4.12. The Caco-2 cell monolayers was intact after 
4h of co-incubation with all 3 formulations, but the majority of the cells were 
detached and lost through washing following a prolongation of the incubation time to 
24h in the presence of WNP and PNP. By comparison, the Caco-2 cell monolayer 
remained relatively intact even after 24h treatment with the P/CreEL formulation.  
 
To detect whether there were any nuclei fragmentation indicative of apoptosis, the 
cell nuclei were stained with Hoechst 33342 and the cells examined under the 
microscope. The nuclei of control Caco-2 cells showed homogeneous fluorescence 
with no evidence of segregation and fragmentation (Figure 4.13), and this was also 
observed of cells exposed for 4h to the WNP, PNP and P/CreEL formulations. In 
contrast, the cell nuclei became severely fragmented after 24h of incubation with 
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WNP and PNP, yielding segments of dense fluorescence, suggesting a major 
breakdown in the chromatin. By comparison, cells treated with P/CreEL for 24h 
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WNP                                           
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P/CreEL  
     
Figure 4.13 Typical microscopic images of Caco-2 cells following 4 and 24h 
incubation with WNP, PNP and P/CreEL formulations. Cell nuclei were stained with 
Hoechst 33342. 
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(c)                                  (d) 
*: R1: sub-G1 phase, dead cell; R2: G1 phase; R3 S phase; R4: G2/M phase 
Figure 4.14 Histograms showing the cell cycle distribution of Caco-2 cells after 4h 
















   
(c)                                (d) 
*: R1: sub-G1 phase, dead cell; R2: G1 phase; R3: S phase; R4: G2/M phase 
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Figure 4.15 Histograms showing the cell cycle distribution of Caco-2 cells after 24h 








































Figure 4.16 Quantitative analysis of the cell cycle distribution of Caco-2 cells 
co-cultured with paclitaxel formulations for (a) 4h and (b) 24h. CON (Control cells) 
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Classification of the Caco-2 cells into the various phases of the cell cycle after their 
incubation with the different paclitaxel formulations is shown in Figures 4.14 and 
4.15. Co-incubation with all 3 paclitaxel formulations for 4h did not change the cell 
cycle distribution patterns of the Caco-2 cells greatly. The WNP and P/CreEL 
formulations caused a slight accumulation of cells in the G2/M phase after 4h of 
exposure, as reflected by the increase in percentage of cells from 28.45% (control) to 
34.88% (WNP) and 36.72% (P/CreEL) in this phase, respectively. Prolonging the 
incubation to 24h with the WNP resulted in substantial cell death (47.93%), 
suggesting that the capacity of WNP to kill the Caco-2 cells was time-dependent. The 
death rates for cells exposed to the PNP and P/CreEL formulations for 24h were 
23.5% and 18.22%, respectively, and these cells also showed a slight increase in the 
G2/M population. The collective data suggest that the three formulations were 
effective in inducing the arrest of cell growth, with WNP being the most effective 
formulation. 
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Figure 4.17 Typical images of Caco-2 cells showing the intracellular trafficking of   
WNP following incubation of the cells with the formulation for various time periods. 
WNP nanoparticle has green fluorescence, cell nuclear is blue, and the overlap of 
nanoparticle and lysotracker® fluorescence (red) is shown as yellow.  
 
Confocal analysis of Caco-2 cells incubated with fWNP demonstrated the uptake of 
the nanoparticles into the intracellular space (Figure 4.17). We stained the acidic 
compartments (endo-lysosomes) and nucleus of the cell with Lysosensor DND-99 
(red) and Hoechst 33258 (blue), respectively, so that the co-localization of 
endo-lysosomes (red) and WNP (green) may be represented by yellow clusters. 
However, the yellow clusters were visible only if the red and green intensities are 
close to each other, thus limiting interpretation from visual inspection alone. To 
provide a quantitative estimate of the degree of co-localization of WNP and 
endo-lysosomes, the confocal images were processed with the program ImageJ 
(National Institutes of Health Bethesda, Maryland, USA). Data represent mean values 
calculated from the Z-series images of cells sequentially obtained by confocal laser 
scanning microscopy. This method was preferred to the use of a single confocal image, 
which represented only a thin slice of the whole cells, and might not be representative 
of the true distribution of endo-lysosomal compartment and nanoparticles in the 
whole cell.  
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Time (h) Colocalisation (yellow) 
(%)  
Green in red (%) Red in green (%) 
0.5 11.29 32.75 33.56 
1 12.75 32.02 29.15 
2 13.96 43.80 34.52 
3 25.42 53.99 44.90 
Table 4.3 Colocalisation of FITC-WNP (green) and endosome/lysosome (red) in 
Caco-2 cells. Colocalisation percentage is the percentage of voxels which have both 
red and green intensities above threshold, expressed as a percentage of the total 
mumber of pixels in the image. 
 
The data show that fWNP was internalized rapidly and could be detected inside the 
cells after 30 min incubation, both in the endo-lysosomes (yellow) and the cytoplasm 
(green). The intensity of green fluorescence in the cytoplasm increased with 
incubation time, which correlates with the increasing amount of internalized WNP 
with time (section 4.4.3). The containment of the internalized WNP in the late 
endo-lysosomal compartments also increased with incubation time, with 33% of the 
internalized fWNP estimated to be colocalized with the acidic compartments at 1h, 
and almost 54% in 3h. Nevertheless, the green fluorescence in the cytoplasm suggests 
that endocytosed fWNP was successfully released from the endo-lysosome into the 
cytoplasm. This release and the subsequent dissociation of paclitaxel from the WNP 
nanoparticles would be imperative for the drug to exert its pharmacological action 
through binding with the cellular tubulin.  
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Figure 4.18 Typical confocal image of Caco-2 cells pre-treated with unlabelled WGA 
and then incubated with fWNP for 3h.  
 
When the Caco-2 cells were pre-treated with unlabelled WGA prior to exposure to 
fWNP, the uptake of fWNP was greatly reduced. Figure 4.18 show a typical confocal 
image of the cells taken after 3h incubation with fWNP. The significant absence of 
green fluorescence in these cells indicated a poor uptake of fWNP. The inhibition of 
fWNP uptake by pre-incubation with unlabelled WGA suggests the fWNP uptake 
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4.5 Discussion 
In many cases, chemotherapeutic treatment of tumors is limited by the inefficient 
intracellular delivery of the anticancer agents in current use. The drugs are not 
specific in their action, with the result that they accumulate not only in the tumor cells 
but also in healthy tissues. This provides the impetus for new approaches that can 
deliver anticancer drugs more specifically to the target organs in order to reduce their 
toxicity (Massing & Fuxius, 2000). Systems capable of intracellular delivery of drugs 
have been extensively studied for genes and anticancer agents (Devalapally et al., 
2008; Lavigne et al., 2008). For some drugs, whose targets are in the cytoplasmic or 
other intracellular compartments, such as the nucleus or mitochondria, it is necessary 
for the drug or delivery system to be delivered to these specific locations in order for 
the drug to exert its pharmacological effect. Such is the case for paclitaxel, whose 
anticancer activity is realized by its  effective binding to the intracellular 
microtubules (Andreopoulou & Muggia, 2008). In addition to a targeted drug 
disposition, the duration of drug retention at the target site could be another critical 
factor to achieve the desired therapeutic outcome in cancer treatment. Cancer is a 
disease condition that requires prolonged drug exposure to ensure complete regression 
of the tumor and avoidance of a relapse (Jang et al., 2003). Some studies have shown 
that anticancer drugs bound to polymeric nanoparticles have prolonged retention in 
tumors, and are consequently more effective in reducing tumor growth and increasing 
Page 136 
 
Chapter 4 Evaluation of anticancer activity of WNP 
 
animal survival rates than the corresponding free drugs (Akhtar & Lewis, 1997; Park 
et al., 2006). In particular, nanoparticles formulated with the PLGA polymer offer a 
nontoxic and efficient carrier system for the sustained intracellular delivery of various 
therapeutic agents (Panyam & Labhasetwar, 2004; Prabha & Labhasetwar, 2004; 
Sahoo & Labhasetwar, 2005). 
 
This study evaluated the anticancer activity of different paclitaxel formulations (WNP, 
PNP and P/CreEL) on the colon cancer cells, Caco-2 and HT-29, and on the colon 
fibroblast cells, CCD-18Co. The CCD-18Co cell line served as a control in our study, 
and its use permitted an evaluation of the specificity of the paclitaxel formulations 
towards cancer cells. 
 
Our hypothesis was that the WGA-conjugated PLGA nanoparticle platform was a 
promising strategy to improve the bioavailability and intracellular retention time of 
paclitaxel. In vitro anti-proliferation studies of the three colon cell types suggested 
that the incorporation of WGA enhanced the cytotoxicity of the paclitaxel-loaded 
PLGA nanoparticles on the cancer cells. Between the 2 colon cancer cell types, the 
HT-29 cells were more sensitive than the Caco-2 cells to the effects of WNP, which 
correlated to its greater sensitivity to the anti-cytoproliferation effects of free 
paclitaxel. WNP was also significantly more cytotoxic towards the Caco-2 cells than 
Page 137 
 
Chapter 4 Evaluation of anticancer activity of WNP 
 
the CCD-18Co cells at 72h, which was in keeping with the uptake data. This indicated 
that the boosted cytotoxicity observed for WNP was a result of enhanced intracellular 
paclitaxel concentration. The WNP and PNP formulations showed comparable IC50 
values with the P/CreEL formulation against Caco-2 cells after 24h co-incubation. 
The IC50 of paclitaxel when delivered as WNP against the Caco-2 and HT-29 cells 
were, respectively, 1.6- and 4.9-folds lower than those of P/CreEL after 72h 
incubation. In the case of the PNP formulation, it was more cytotoxic against the 
colon cancer cells than against the CCD-18Co cells at 24h incubation, but the 
differential cytotoxicities were no longer apparent when the incubation time was 
prolonged to 72h. The conventional formulation, P/CreEL did not exhibit clear 
differential cytotoxicity profiles towards the cancerous and normal colon cells at 24h 
and 72h.  On this basis, the WNP could be considered a superior paclitaxel 
formulation compared to PNP and P/CreEL.  
 
The WNP showed time-dependent paclitaxel IC50 values for all three colon cell types, 
indicating a prolonged incubation time was required to raise the intracellular drug 
concentration to therapeutic level. This time lag could be required for the drug to be 
released from the nanoparticles in the cell cytoplasm. Nevertheless, the paclitaxel 
IC50 values attained with the WNP formulation were consistently lower than those 
obtained with the P/CreEL and PNP formulations tested under similar conditions. The 
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greater efficacy of WNP correlated well with the higher cellular uptake and sustained 
intracellular retention of paclitaxel associated with the formulation. The cellular 
uptake and retention efficiency for WNP might be attributed to the over-expression of 
N-acetyl-D-glucosamine-containing glycoprotein on the colon cell surface (section 
2.4.2). In particular, binding of the conjugated WGA to glycoproteins expressed on 
the cytoplasmic side of the cell membrane could be potentially useful for facilitating 
the intracellular retention of WNP. In addition, WGA conjugation has been observed 
to decrease the negative surface charge of PLGA nanoparticles, and this in itself could 
enhance interaction of the nanoparticles with the cell membrane. In contrast, the 
higher negative surface charge of the PNP formulation could pose a challenge to 
nanoparticle entry into the cells. 
 
Paclitaxel has an intracellular pharmacological target. Any nanoparticle formulation 
of paclitaxel must therefore ensure drug access intracellularly. For most such 
formulations, the nanoparticles would have to first gain access into the cells before the 
drug could be released to exert its effect. Paclitaxel uptake from the WNP formulation 
at 2h incubation was the highest in the Caco-2 cells compared to the other two cell 
lines. On the other hand, the CCD-18Co cells showed comparable uptake of paclitaxel 
from the WNP and PNP formulations, which could be indicative of the fibroblast cells 
having a higher non-specific rate of endocytosis than cancerous cells Caco-2 and 
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HT-29. The two colon cancer cell lines, Caco-2 and HT-29 cells, showed preferential 
uptake of WNP compared to PNP, suggesting that WGA conjugation to the PLGA 
nanoparticles was advantageous in facilitating the nanoparticle uptake by the cultured 
colon cancer cells. To differentiate between the WNP bound to the cell membrane and 
the WNP taken up into the cell, TB was used to quench the membrane bound 
fluorescence so that any fluorescence detected could be attributed to the internalized 
WNP. Our results confirmed that most of the cell-associated fluorescence was located 
intracellularly. The implication is that WNP was successfully taken up into the cells. 
The uptake mechanism was further confirmed to be mediated by WGA, as it was 
readily inhibited by the presence of unlabelled WGA. 
 
We predict that WGA-conjugated nanoparticles would increase the residence time of 
drugs in the colon due to their interaction with mucins and intestinal epithelium for 
extended periods, promoting penetration of active drug through and between cells due 
to the concentration gradient between nanoparticles and intestinal membrane. In this 
study, we proposed that the uptake of WGA-conjugated nanoparticles via 
WGA-mediated endocytosis could have an intracellular disposition pathway different 
from that of unconjugated nanoparticles. This would result in different levels of 
intracellular retention of nanoparticles and hence therapeutic efficacy of the 
encapsulated paclitaxel. Although the phenomenon of greater cellular uptake of drug 
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and drug delivery systems following WGA conjugation has been known (Gabor et al., 
2004; Mo & Lim, 2005), the effect of such conjugation on drug retention inside the 
cells has not been investigated. Our results showed that WGA conjugation on the 
surface of PLGA nanoparticles could indeed increase the retention of paclitaxel inside 
the colon cancer cells. It should be pointed out that the advantages of WNP versus 
P/CreEL would be much more significant if the enhanced cellular uptake, as well as 
intracellular drug retention and sustainable drug release features were included. 
 
The endocytic and intracellular trafficking pathways are complex and highly regulated 
processes. Following endocytic uptake, nanoparticles may be transferred into early 
sorting endosomes and recycling endosomes or transferred from early endosomes to 
late endosomes -lysosomes (Richardson et al., 2008). The late endosomes and 
lysosomes have a relatively low pH (5.0 ~ 6.0) and they contain digestive hydrolases 
such as nucleases, glycosidase, lipases and phosphotases (Alberts et al., 2002). 
Endosomal escape has been reported for PLGA nanoparticles in gene delivery (Ng et 
al., 2009). Our study showed about 30% of the endocytosed WNP to be present in the 
late endo-lysosomes.  Fluorescence attributed to WNP in the cytosolic compartment 
was observed to increase with incubation time, suggesting successful escape of the 
WNP from the endo-lysosome compartment into the cytosol. The escape mechanism 
might be provided by a reversal ( from anionic to cationic) of the negative charge on 
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the PLGA nanoparticle surface when confronted with the acidic pH in the 
endo-lysosomes compartment (Panyam et al., 2002). The progression of events from 
cell entry to eventual drug release from the nanoparticles would account for why cell 
damage/death occurred only after prolonged incubation when WNP was internalized 
at a rapid rate into the cells. The induction of cell apoptosis, together with an arrest of 
the cell cycle at the subG1 and G2/M phases, was observed after 24h exposure to 
WNP, as demonstrated by changes in cell detachment, nuclear morphology and cell 
cycle distribution. By comparison, P/CreEL and PNP at equivalent paclitaxel doses 
produced a lower level of l apoptosis under the same test conditions.  
 
4.6 Conclusion 
WNP had superior in vitro anti-proliferation activity against the colon cancer cell 
lines, Caco-2 and HT-29, compared with the PNP and P/CreEL formulations and it 
was less toxic against the normal CCD-18Co cells than against the cancer cells. The 
enhanced cytotoxicity of WNP in the colon cancer cells could be attributed to a more 
efficient cellular internalization of paclitaxel via WGA-mediated endocytosis, and a 
more efficient retention of the drug within the cells. The anti-cytoproliferation activity 
of WNP was dependent on incubation time and loading concentration, with a time 
delay noted between WNP internalization by the cells and significant cell death by 
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apoptosis. Co-localization studies indicated that WNP could escape from the 
endo-lysosomal compartment into the cytosol.  
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5.1 Introduction 
The gastrointestinal epithelium, cancer tissue and other mucosa are usually covered 
by mucus. Mucus is present as either a gel layer adherent to the mucosal surface or as 
a soluble or suspended form in the lumen (Smart 2005). It is a mixture of large 
glycoproteins, lipids, enzymes, water, electrolytes, sloughed epithelial cells, bacteria 
and bacterial products (Allen et al. 1990; Rathbone and Hadgraft 1991). The two 
major components are water, which accounts for more than 95% by weight (Smart 
2005), and mucins, which gives the highly hydrated mucus a characteristic gel-like 
consistency with cohesive and adhesive properties. Mucins are glycoproteins and the 
chief determinants of the functional and physical properties of mucus (Wirth et al. 
2002). They have been identified in two major forms, soluble secretory mucin, which 
is oligomeric and thought to be responsible for the rheological properties of mucus, 
and membrane bound mucin, which is monomeric (Filipe 1979; Strous and Dekker 
1992; Thornton and Sheehan 2004). There are at least eight different human genes for 
mucins, each mucin gene is highly polymorphic, several different mucin genes are 
expressed at each type of mucosal surface, and some epithelial cells expressed more 
than one mucin gene (Gendler and Spicer 1995). 
 
The colonic mucosa, like other exposed epithelial surfaces, is covered by a mucus 
layer which protects the underlying epithelium against mechanical, biological and 
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chemical irritants (Aksoy and Akinci 2004). The mucous layer has varied thickness 
that decreases in the order of rectum, sigmoid colon, transverse colon, ascending 
colon, and caecum (Matsuo et al. 1997). Depending on the method employed for 
measurement, the colonic mucous layer has been reported to have thickness of 
between 50 and 450 µm (Sonju et al. 1974; Kerss et al. 1982; Allen et al. 1990), and 
an estimated turnover time equivalent to the gut transit time of 24 – 48 h (Duchene et 
al. 1988). Human colonic mucosa synthesizes and secretes mucins to form the 
visco-elastic mucous barrier on the luminal side. The secreted mucins do not only 
constitute a physical barrier against the extracellular environment, but is also selective 
towards substances for binding and uptake by the epithelia (Matsuo et al. 1997).  
 
Alterations in intestinal mucin constitution, especially in the glycosylation pattern and 
expression level, are thought to be associated with diseases such as inflammatory 
bowel disease and carcinoma (Ho et al. 1993; Tytgat et al. 1993). However, mucin 
apoprotein and glycosylation patterns during colorectal carcinogenesis is not 
well-defined (Aksoy et al. 2000). Almost all carcinomas of the colon produce mucin, 
although the most aggressive tumours, classified as mucinous cancers, make up 10 to 
20% of all colon cancers (Park et al. 2008). Mucinous cancers are characterized by 
abundant production of the goblet cell mucin, MUC2 (Naves et al. 1985; Nozoe et al. 
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2000), but this is also the prominent mucin in normal human colon (Tytgat et al. 
1994).  
 
An abundant gel-like mucous layer can impede drug delivery to colon cancer cells, 
but it also provides an opportunity for sustained or prolonged drug delivery via the 
development of mucoadhesive delivery systems (Longer et al. 1985; Lejoyeux et al. 
1989). Mucoadhesive delivery platforms are designed to attach to mucus or a mucous 
membrane in vivo (Smart 2005) so as to prolong and intensify drug contact with the 
underlying mucosal tissue (Junginger 1990).  
 
In this regard, the interaction between mucin and particulate drug delivery system is 
an important consideration in the understanding of transmucosal drug absorption from 
nanoparticles. The dynamics of particles in solutions and in gel networks are hard to 
predict theoretically and therefore need to be characterized experimentally. 
Fluorescence recovery after photobleaching (FRAP) is a noninvasive measurement 
technique capable of quantifying particle diffusion and immobilization in 
pharmaceutical matrices as well as in tissues and cells (Kaufman and Jain 1991), and 
it allows for the study of particle mobility and interactions in small, intact tissue 
samples (Meyvis et al. 1999). First proposed by Elson and Reidler (Elson and Reidler 
1979) and later expanded by Koppel (Koppel 1981) and Thompson et al. (Thompson 
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et al. 1981), FRAP is based on laser photobleaching of a small region of a specimen 
labeled with a fluorescent molecule. Following the photobleaching laser pulse, the 
recovery of fluorescence due to diffusion and/or flow from the surrounding 
unbleached areas into the bleached area is monitored with the same but much 
attenuated laser beam and a photomultiplier tube. The rate of recovery is related to the 
diffusion coefficient or flow velocity of the fluorescent molecule (Tsay and Jacobson 
1991). FRAP has been used to detect macromolecules and particles  binding or 
diffusing in cell membranes (Jacobson et al. 1995), cytoplasm (Seksek et al. 1997; 
Partikian et al. 1998), mucus (Olmsted et al. 2001) and various in vitro preparations 
(Kaufman and Jain 1991; Olmsted et al. 2001). 
 
The aim of the experiments in this section of the study was to investigate the effects 
of mucin on the uptake and cytotoxicity of WNP by/against colonic cells. Mucin 
secretion by the colon cancer cell model, LS174T, was first investigated by 
histochemical staining and lectin blot before the FRAP technique was applied to 
evaluate the diffusion of WNP in the secreting mucin layer of LS174T cells. The 
LS174T cell line is derived from human colon cancer cells with mucous granules that 
secrete significant amounts of mucin, similar to goblet cells (Kuan et al. 1987; Kuan 
et al. 1987). The cells have goblet cell-like characteristics, and have been shown to 
synthesize several mucins of which the secretory MUC2 was most prominently 
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expressed (VanKlinken et al. 1996). LS174T cells mimic the mucin expression in the 
colon and provide a good in vitro model for mucin-expressing colon cells. Taken 
together, LS174T cell line could be an appropriate in vitro model for assessing 
mucoadhesion. 
 
There are many histochemical methods available for the identification of different 
types of mucins (Culling et al. 1975; Jansen 1995; Bancroft and Gamble 2008). 
Histochemical techniques for the localization and differentiation of acidic and neutral 
mucins are based on selective detection of vicinal diols by their reactivity with the 
periodic acid Schiff (PAS) procedure, and the affinity of the anionic groups towards 
the cationic dyes (Yashpal et al. 2007). Alcian blue (AB), a group of water-soluble 
polyvalent basic dyes, is the most commonly used cationic dye for the demonstration 
of acid mucins. The blue color is due to the presence of copper in the molecule. At pH 
2.5, AB stains both sulfated and carboxylated acid mucopolysaccharides and sulfated 
and carboxylated glycoproteins. It is believed to form salt linkages with the acid 
groups in these mucopolysaccharides (Bogomoletz 1986). The PAS stain is applied to 
detect neutral and acidic polysaccharides. It oxidizes the carbon to carbon bond to 
form aldehydes, which react with fuchsin-sulfurous acid to yield a magenta product 
(Bogomoletz 1986). Optimum staining of acidic, neutral and mixtures of acidic and 
neutral mucins in tissue are obtained by combining the AB and PAS techniques 
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(Bancroft and Gamble 2008). The rationale is to first apply AB to stain all the acidic 
mucins, including those which are also PAS positive so that these are blocked from 
further reaction with PAS. Subsequent application of PAS will therefore detect only 
the neutral mucins, allowing these to be stained in a contrasting manner 
(magenta/pink) to the acidic mucins (blue). For cells that contain an admixture of 
mucin types, the resultant stain will be an intermediate color between magenta and 
blue, depending on the dominant moiety present. 
 
5.2 Materials 
Materials listed in Section 3.2 were used in this study. In addition, the LS174T cell 
line (passage 109) was obtained from the American Type Culture Collection. Eagle 
MEM, and the Alcian blue (AB) and periodic acid Schiff (PAS) staining systems were 
products of the Sigma Chemical Co. 
 
5.3 Methods 
5.3.1 Cell culture 
LS174T cells were cultured in Eagle’s MEM supplemented with 100 U/ml of 
penicillin, 100 μg/ml of streptomycin and 10% (v/v) of FBS. Cell cultures were 
incubated at 37°C in a humidified atmosphere of 5% CO2 and 95% air, with medium 
exchange on alternate days. Cells were subcultured every 3 days after trypsinization. 
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5.3.2 Alcian blue (AB) and periodic acid Schiff (PAS) staining 
LS174T cells were cultured in a Lab-Tek chamber at a seeding density of 1.0 × 104 
cells/cm2. After 3 or 6 days culture, the cells were fixed with an ethanol-acetic acid 
(3:1) solution, air-dried, and stained with AB (3% solution in acetic acid, pH 2.5) for 
10 min. Following rinsing with PBS three times, the cells were stained with PAS 
according to the manufacturer’s instructions (treatment with a 0.5% periodic acid 
solution for 5 min at room temperature, followed by Schiff reagent for 15 min). The 
cells were then counter-stained with hematoxylin for 90 s, and washed with PBS 
before examination under a microscope (Nikon, Nikon Instruments Inc., Kanagawa, 
Japan). 
 
5.3.3 Lectin blot 
LS174T cells were cultured on 25 cm2 flasks at a seeding density of 1.0 × 104 
cells/cm2 for 3 or 6 days. Confluent cells were washed thrice with ice-cold PBS, then 
scraped off into PBS with a cell scraper. Cell membrane protein and intracellular 
protein were extracted using the Mem-PER eukaryotic membrane protein extraction 
reagent kit (Pierce Biotechnology, Rockford, IL, USA) according to the 
manufacturer’s instructions as described in section 2.3.3. A 7.5% polyacrylamide 
resolving gel and a 4% stacking gel were prepared as described in section 2.3.5. 
Samples equivalent to 5 µg of protein were size-fractionated by electrophoresis and 
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transferred to PVDF membranes as described in section 2.3.5. The glycoprotein was 
detected using the west pico chemiluminescence system. Bands were visualized in a 
CCD imaging machine. 
 
5.3.4 Cytotoxicity of WGA 
To assess the cytotoxicity of WGA against the LS174T cells, the cells were seeded 
onto 96-well plates at a density of 8,000-10,000 cells/well. Confluent cells were 
washed with 3 × 200 μl of PBS before incubation with 200 μl of WGA solution (10 to 
200µg/ml) for 4 to 72h. The MTT assay was performed according to the protocols 
described in section 3.3.2. 
 
5.3.5 Uptake of FITC-WGA 
LS174T cells were seeded onto 96-well plates at a density of about 1.0×105 cells/ well. 
Confluent cells on Day 3 were washed twice with 200 μl of HBSS/HEPES (HBSS 
buffered with 10 mM of HEPES to pH 7.4) before uptake experiments were 
performed according to the method described in section 3.3.4. 
 
5.3.6 Anti-proliferation activity of paclitaxel-loaded nanoparticles 
For anti-proliferation experiments, LS174T cells were plated at 10,000 cells per well 
and subjected to treatment with various doses of the investigational formulations as 
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free drugs or encapsulated in PLGA nanoparticles diluted in supplemented medium. 
Treatment with serum-supplemented medium was used as a negative control (0% cell 
death). WNP, control formulations PNP and P/CreEL were prepared as described in 
section 4.3.1. 
 
5.3.7 Cellular uptake and efflux of paclitaxel 
LS174T cells were cultured in 12-mm petri dishes for 3 or 6 days at a seeding density 
of 1.0 × 104 cells/cm2. Intracellular uptake experiments were initiated by the addition 
of 6 ml of HBSS/HEPES containing appropriate concentrations of WNP, PNP or 
P/CreEL to give 40 µg/ml of paclitaxel in each dish. After 2h incubation at 37 ˚C, the 
cells were immediately washed thrice with ice-cold PBS, harvested with a rubber 
scraper and centrifuged at 10,000 x g for 10 min. Cell pellets were lysed in 300 µl of 
methanol under sonication, and the supernatant was separated by centrifugation. The 
drug content in the supernatant was measured by high performance liquid 
chromatography (HPLC), and expressed as the amount of intracellular paclitaxel (µg) 
per mg of total cell protein. 
 
To estimate the efflux rate of paclitaxel, subconfluent cells in 12-mm petri dishes on 
day 3 or 6 were incubated with 6 ml of WNP in HBSS/HEPES for 2 h. After washing 
with PBS, the cells were further incubated with fresh medium devoid of drug for 
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another 2 h at 37 ˚C. The cells were washed with PBS three times before they were 
harvested with a rubber scraper. The paclitaxel content of the harvested cells was 
quantified by HPLC analysis and expressed as the amount of paclitaxel (µg) per mg 
of total cell protein. 
 
A HPLC method was developed and validated for the quantification of paclitaxel. 
Chromatographic separation was achieved on an Agilent 1100 system (Agilent 
Technologies, Palo Alto, CA) using a C18 column (200× 4.6 mm, 5 µm) (Waters, 
Milford, MA) preceded by a guard column (Waters), flow rate of 1 ml/min and UV 
detection at 229 nm. The mobile phase consisted of acetonitrile and water at a volume 
ratio of 1:1. A linear standard curve was obtained over the paclitaxel concentration 
range of 0.1 to 10 µg/ml in methanol (R2 > 0.99). The relative standard deviations 
(RSD) for day-to-day and within-day precisions for this assay were less than 10%. 
The HPLC peaks were recorded and integrated using the Agilent data analysis 
software.  
 
5.3.8 Diffusion measurements (FRAP) 
In this study, we aimed to investigate the diffusion property of nanoparticle fWNP in 
PBS and mucin layer. To investigate the influence of interaction of WGA and its 
receptor in mucin on the nanoparticle’s diffusion, we studied the diffusion of fWNP 
Page 154 
 
Chapter 5 Effect of mucin on the uptake of nanoparticles 
 
and BSA-NP in mucin layer of LS174T cells. LS174T cells were cultured in Lab-Tek 
chambere at a seeding density of 1.0 × 104 cells/cm2. After 6 days, the cells were 
rinsed twice with prewarmed HBSS/HEPES and preincubated for 30 min at 37°C 
with 0.2 ml of HBSS/HEPES before they were separately incubated for 1 h at 37 °C 
with 0.2 ml of the fWGA, fWNP, and fBSA-NP (FITC-BSA conjugated PLGA 
nanoparticles) samples (HBSS/HEPES as vehicle). In order to tell the diffusion 
difference between the small molecule fWGA and fWGA-conjugated nanoparticles, 
the diffusion of fWNP and fWGA was also investigated in PBS. The cells were 
analyzed as follows: an attenuated laser beam focused onto an area of the mucus layer 
on the cell surface was gradually increased in intensity to approximately 103 to 104 
fold, causing a rapid bleaching of the fluorescent molecules in the area. Residual 
fluorescence in the same area was monitored by an attenuated laser beam, which 
showed the fluorescent signal returned to a new steady-state value as unbleached 
probes from the surrounding areas diffused into the partially bleached area. The rate 
of recovery of fluorescence was calculated as a measure of the rate of diffusion of the 
fluorescent particles in the sample, the fractional recovery of fluorescent signal 
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5.3.9 Visualization of fWNP uptake by LS174T cells 
LS174T cells were grown on Lab-Tek chamber at a density of 1.0 × 104 cells/cm2, and 
incubated at 37°C in 95% air/5% CO2 environment overnight. On the 3rd or 6th day 
post-seeding, the cell monolayers were rinsed twice with prewarmed HBSS/HEPES 
and preincubated for 30 min at 37°C with 0.2 ml of HBSS/HEPES before they were 
incubated for 1 h at 37 °C with the fWNP sample (1 mg/ml in HBSS/HEPES). TB 
was used to extinguish the outside fluorescence of the cells as described in section 
3.3.5. Uptake was terminated by washing the cells thrice with ice-cold PBS. The cells 
were fixed by incubation for 10 min in 0.5 ml of acetone/methanol (1:1) at 0 °C, and 
observed under a confocal laser scanning microscope. 
 
5.3.10 Statistical analysis 
Data are presented as mean ± standard deviation. Differences between mean values 
were analyzed for significance by one-way ANOVA using the SPSS 10.0 software. P 
values ≤ 0.05 were considered significantly different. 
 
5.4 Results 
5.4.1 Alcian blue (AB) and periodic acid Schiff (PAS) staining 
AB and PAS staining study of the LS174T cells showed a marked increase in neutral 
and acidic mucopolysaccarides on the cell surface following prolonged culture 
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(Figure 5.1). The profusion of magenta and blue spots in Figure 5.1a suggests 
extensive mucin coverage of the cells after 6 days of culture, although a significant 
amount of mucin glycoprotein was also produced after 3 days of culture (Figure 5.1 b). 
These images confirmed an intact mucin secretory function for the LS174T cell line 
used in the study. 
 
   
Figure 5.1 Alcian blue and PAS staining of mucin in LS174T cells following (a) 6 
days culture and (b) 3 days culture. Cells were observed at magnification of 10×. 
 
5.4.2 Lectin blot analysis 
SDS-PAGE analyses detected WGA-reactive glycoproteins in the cell membrane and 
cytoplasm of the LS174T cells. Multiple proteins with molecular size ≥ 75 kDa were 
detected (Figure 5.2), the number of proteins increasing after 6 days of culture 










       
(a)              (b) 
Figure 5.2 Lectin blot analysis for WGA-recognizable proteins among the (a) cell 
membrane proteins, and (b) intracellular proteins in the LS174T cells. Lane 1 - 3 days 
of culture; lane 2 - 6 days of culture. 
 
5.4.3 In vitro cytotoxicity profile of WGA against LS174T 
The viability of LS174T cells was not significantly affected by up to 72h incubation 
with WGA. Even when exposed to high WGA concentrations of 100 and 200 µg/ml, 
the viability of the LS174T cells did not fall below 80% at any of the incubation time 
points studied (Figure 5.3). There were no significant differences in cell viability 
either at different WGA concentrations or upon prolonged incubation, suggesting that 
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Figure 5.3 In vitro cytotoxicity profiles of WGA against the LS174T cells as a 
function of exposure time. WGA was applied at loading concentrations of 0.1, 1, 5, 10, 
50, 100 and 200 μg/ml. Cell viability determined by the MTT assay was expressed as 
a percent of that obtained for cells exposed to culture medium. Data represent mean ± 
SD, n=6. 
 
5.4.4 Uptake of FITC-WGA 
Uptake of fWGA by the LS174T cells was studied at fWGA loading concentrations of 
5, 10, 20 and 50 µg/ml, and the data were normalized against the cellular protein 
content. At all fWGA loading concentrations, cellular fWGA uptake by the LS174T 
cells increased with prolongation of incubation time from 0.5 to 5h. Cellular uptake 
was rapid. The amount of fWGA associated with LS174T cells at 30 min were 
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5.3±0.2, 7.7±0.4, 10.2±0.3 and 13.6±0.2 μg WGA/mg cell protein at the loading 
concentration 5, 10, 20 and 50µg/ml, respectively. These correspond to 15%, 11%, 






























Figure 5.4 Uptake of fWGA by LS174T cells as a function of incubation time (Data 
represent mean ± SD, n=4) 
 
5.4.5 Antiproliferation activity of paclitaxel-loaded nanoparticles 
Figure 5.5 showed cytotoxicity of WNP, PNP and P/CreEL against LS174T cells. The 
cell viability decreased as we increased the concentration of nanoparticles and 
incubation time. The result showed there was no significant difference of the 
cytotoxicity at 24h. However, when the incubation time was prolonged to 72h, WNP 
showed advantages in achieving lower cell viability compared to PNP and P/CreEL (p 
< 0.05).  
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Figure 5.5 In vitro cytotoxicity of P/CreEL, PNP and WNP against LS174T cells (n = 
6). ‘*’ indicates statistical significance compared to PNP (p < 0.05). 
 
5.4.6 Cellular uptake and efflux of paclitaxel 
Figure 5.6 showed the data for cellular paclitaxel uptake from the WNP, PNP and 
P/CreEL samples by the LS174T cells at 3 and 6 days of culture. Cells at 3 days of 
culture had been shown to produce less mucin than those cultured over 6 days. The 
difference in mucin production did not, however, caused the cells to show significant 
differences in paclitaxel uptake from the WNP, PNP and P/CreEL samples, although 
an upward trend in cellular uptake was noted in the 6-day old cells. On the other hand, 
the LS174T cells, regardless of the days in culture, showed much higher cellular 
uptake of paclitaxel from the nanoparticle formulations, WNP and PNP, than from the 
P/CreEL formulation. These results were consistent with Caco-2 and HT-29 cells, 
which were not known to be mucin-producing colonic cells. Therefore, it may be 
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concluded that the presence of mucin on the LS174T cell surface did not impede 
























































Figure 5.6 Cellular uptake and intracellular retention of paclitaxel from the WNP, 
PNP and P/CreEL formulations by the LS174T cells following (a) 3 days of culture; 





Chapter 5 Effect of mucin on the uptake of nanoparticles 
 
5.4.7 Diffusion measurements (FRAP) 
FRAP plots showing fluorescence recovery as a function of time was fitted to a single 
exponential function (Figures 5.7 and 5.8) and the corresponding parameters compiled 
in Table 5.1. The “mobile fraction” refers to the fraction of fluorescent molecules that 
were free to move within the bleached region while “half-time for recovery” was the 
time taken to reach 50% of the steady state fluorescence. The FRAP plots suggest that 
significant portions of the fWGA molecules and fWNP nanoparticles in the PBS 
vehicle were mobile, the observed recovery rates reaching 93 and 76%, respectively. 
Although fWGA had significantly higher steady state fluorescence (plateau value of 
the recovery curve) implicating a greater mobile fraction, the two species had 
comparable recovery half-times. By comparison, fWNP had an almost 8-fold slower 
recovery half-time in the mucus layer of the LS174T cell sample (Table 5.1). The 
mucus layer did not only slow down the diffusion of fWNP, but also impeded the 
overall mobility of the nanoparticles, reducing the mobile fraction to only 49%. These 
results were comparable to those obtained for fBSA-NP. In addition, a higher 
variability in mobility of the fWNP nanoparticles was noted in the cell sample than in 










Figure 5.7 Fluorescence recovery curves of fWNP and fWGA in PBS solution 
 
 
Figure 5.8 Fluorescence recovery curves of fWNP and fBSA-NP in the surface mucin 
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Table 5.1 Mobile fraction and half-time to steady state fluorescence obtained from the 
FRAP plots for fWGA, fWNP and fBSA-NP particles in PBS and the mucin layer of 
LS174T samples (Mean ± SD, n=4) 
Sample Mobile fraction Half-time (s) 
fWGA PBS 0.93±0.06 1.3±0.34 
fWNP 
PBS 0.76±0.05 1.5±0.14 
Mucin layer 0.49±0.07 11.5±5.7 
fBSA-NP Mucin layer 0.59±0.16 7.5±4.9 
 
5.4.8 Visualization of fWNP uptake by LS174T cells 
Confocal laser scanning microscopic examination before and after trypan blue 
staining indicated that fWNP were not only bound to, but also internalized by the 
LS174T cells (Figure 5.9). Figure 5.9 (b) shows that the fluorescence in the cell 
sample attributed to fWNP was lower following incubation of the cells with trypan 
blue, which would bleach any extracellular fluorescence. The incomplete quenching 
of the fluorescent signals suggests that a significant amount of the cell-associated 
fWNP was internalized by the cells. Figure 5.9 (c) shows the mucin layer on the 
surface of LS174T cells after 1h incubation with fWNP. The plenty of green 




Chapter 5 Effect of mucin on the uptake of nanoparticles 
 




Figure 5.9 Confocal images of LS174T cells incubated with 1.0 mg/ml of fluorescent 
fWNP for 1h; (a) before trypan blue treatment, (b) after incubation for 3 min with 0.2 
mg/ml of trypan blue, and (c) focus on mucin layer 
 
5.5 Discussion 
WGA has been shown to react with cell membrane glycoproteins in a wide variety of 
neoplastic tissues (Bresalier et al. 1990; Mody et al. 1995). Cytotoxicity of LS174T 
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was not affected remarkably by treatment of WGA even at higher concentration, 
while the cytotoxicity of Caco-2 and HT-29 were affected by the concentration of 
WGA and/or the incubation time. In general, the cell viability of Caco-2 and HT-29 
was reduced when the WGA concentration was increased and/or when the incubation 
time was prolonged. Lectin blot analysis showed LS174T cells under 3 days culture 
expressed less WGA-recognized glycoproteins on cell membrane compared to the 
other colon cancer cell line Caco-2 and HT-29. It was found that WGA must be 
internalized to exhibit a cytotoxic effect in the study of pancreatic cancer cells 
(Schwarz et al. 1999). Since there was not much WGA binding sites on the cell 
surface, it is easy to understand that viability of LS174T cells is not affected 
remarkably. The uptake of fWGA by LS174T cells was time and concentration 
dependent. Compared with Caco-2 and HT-29 cells, LS174T cells showed the 
weakest uptake of fWGA at all time points. On the other hand, like the Caco-2 and 
HT-29 cells, cellular uptake of WGA by LS174T cells was rapid followed by 
internalization.  
 
Studies on the mucin production of the LS174T cells has shown the expression of a 
variety of mucin glycoproteins (Kuan et al. 1987; VanKlinken et al. 1996), including 
the MUC1 and MUC2, which are implicated in host-pathogen relationships. Alcian 
blue/PAS staining showed both acidic and neutral mucins were produced by the 
Page 167 
 
Chapter 5 Effect of mucin on the uptake of nanoparticles 
 
LS174T cells after 6 days culturing. Other researchers’ study also showed LS174T 
contained mucinous secretory granules (Kuan et al. 1987). The glycoprotein 
production of LS174T was also examined by lectin blot in this study. Our results 
confirmed there was higher level of WGA-binding glycoproteins both in the cell 
membrane protein fraction and the cytoplasmic protein fraction of 6-day culture 
compared with that of 3-day culture. Due to the water insoluble property of most of 
mucin glycoprotein (Bhavanandan 1991; Carlstedt et al. 1993; Axelsson et al. 1998), 
we could predict most of the mucin glycoprotein was located in cell membrane 
protein fraction. Thus the increase expression of WGA-binding glycoproteins might 
attribute to the production of mucin glycoprotein. 
 
Generally, the presence of overlying mucus is a significant barrier to the permeation 
of lipophilic drugs, and the uptake of hydrophobic nanoparticles by absorptive 
epithelial cells. However, bioadhesive drug delivery systems may overcome this 
barrier by prolonging the residence time and intensifying drug contact with the 
underlying epithelial at the site of drug absorption. Paclitaxel uptake from the WNP 
formulations by the LS174T cells showed no significant differences between the 
3-day culture LS174T (less mucin production) and 6-day culture LS174T (more 
mucin production). This result indicated that the presence of mucin may not be a 
barrier for the uptake of WGA conjugated nanoparticles by LS174T cells. The uptake 
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result also showed there was no significant difference in paclitaxel uptake from the 
WNP and PNP. The binding of fWNP to cell surface ligands and followed 
internalization into the cells was confirmed by Confocal study. The trypan blue 
treated cell layers showed plenty of fluorescence. This means the fluorescence we 
imaged under confocal microscope is the nanoparticles located intracellularly after 1h 
uptake. The interaction of fWNP and mucin glycoprotein on the LS174T cell surface 
was also confirmed by confocal images.  
 
Cytotoxicity study of three paclitaxel formulations showed the three formulations had 
comparable in vitro cytotoxicity against LS174T cells at 24h. However, when the 
incubation time was prolonged from 24h to 72h, WNP began to exhibit significant 
difference of cytotoxicity at the loading concentration of 1 and 0.1 mg/ml. This was 
not consistent with the comparable paclitaxel uptake from WNP and PNP in the 
uptake study. The discrepancy might due to the different study time of uptake and 
cytotoxicity study. The uptake study was terminated at 2h, while the cytotoxicity data 
were obtained at 24 and 72h. Uptake study was not conducted longer due to the 
consideration of cytotoxicity of formulations at longer incubation. Though the uptake 
of WNP by LS174T cells occurred quickly after the co-incubation, the significant cell 
death occurred only at 72h. The reason of the delayed onset probably because the 
retained WNP onto the cell surface and inside the cells need time to transport inside 
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the cells or release the drug at the action site. The interaction of WGA and Mucin 
glycoprotein might be a reason for helping the retention of WNP.  
 
FRAP is a powerful method for measuring the dynamics of biomolecules. It provides 
qualitative and quantitative data that can be useful for a number of biological studies, 
such as particle diffuse in different medium. Our FRAP result showed fWGA could 
diffuse rapidly in PBS. Similar with fWGA, fWNP could also diffuse rapidly in PBS, 
though the mobile fraction is much lower. This matched what would be expected for 
small molecules and large particles in PBS. To investigate whether the nanoparticles 
can diffuse in mucus and whether nanoparticles are retarded by the mesh spacing 
and/or by high-affinity bonds with mucins, we studied the diffusion of fluorescence 
labeled nanoparticles (fWNP) in mucin layer on the LS174T cell surface. Slow 
diffusion of both fWNP and fBSA-NP was detectable with FRAP. fWNP was slowed 
significantly in mucin layer. This is because mucin layer is viscous and fWNP could 
stick to mucin fibers or be hindered by the size of the mesh spacing between the 
mucin fibers. 
 
Our experiments suggested that fWNP and fBSA-NP were capable of diffusing 
through the mucus layer of LS174T cells slowly, though they are retarded by mucin. 
These observations are consistant with the observations that small polystyrene 
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microspheres (415nm) placed in the distal colon of rats were later observed adjacent 
to the mucosa after passing through the mucus layer of the colon (Szentkuti 1997). 
fBSA-NP was partially mobile in our study which indicated that part of nanoparticles 
was trapped by the mesh spacing of mucus layer. fWNP showed a little more 
immobile fraction. This indicated that the motion of fWNP was retarded by both the 
mesh spacing between fibers of mucin and high-affinity bonds with mucins. The 
fWGA on the surface of fWNP sticked to the certain mucin glycoprotein and 
therefore the fWNP was trapped by the mucus gel. Except for the retardness of fWNP, 
the mobile fraction showed fWNP has a certain ability to move through the mucus. 
 
The partial mobility of fWNP is very important for their uptake by the underlying 
cells. If fWNP was completely stuck by mucin fibers, the mucin layer will totally be a 
diffusional barrier for the surfaces they cover. If fWNP could diffuse freely in mucin 
layer, the mucin layer could not help to retain the particles close to the absorption site. 
The partial mobility of fWNP would not only help the particles stay close to the cells, 
thus increasing the concentration gradient of the drug, but also enabled the particles to 
be transported into the cells. Thus, mucin layer could be serving as a bridge between 
the WGA conjugated nanoparticles and the colon cancer cells under the mucin layer 
by using the interaction of mucin glycoprotein and WGA. Our cytotoxicity study 
showed that the WNP exhibited superior cytotoxicity effect at 72 h compared to the 
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In summary, this study has confirmed that LS174T is a mucin producing cell model. It 
may have useful application in screening mucoadhesives under physiological 
conditions. WNP had a certain mobile fraction in mucin layer. This indicated WNP 
could diffuse through the mucin layer slowly. The binding of WGA and the mucin 
glycoproteins could serve for mucoadhesive drug delivery to prolong the residence 
time at the colon site and improve the bioavailability of anticancer drug delivery 
systems. 
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6. Conclusion 
WGA was reported to bind to oligosaccharides containing terminal 
N-acetyl-D-glucosamine and N-acetyl-D-neuraminic acid residues on human 
colonocytes. This project was initiated to prove the hypothesis that the conjugation of 
WGA to PLGA nanoparticles loaded with paclitaxel (WNP) could improve the 
delivery of paclitaxel to colonic cancer cells. WGA, as a targeting moiety, was first 
evaluated for its cytotoxiciy and cellular uptake in colon cancer cell models, 
represented by the Caco-2 and HT-29 cells. The colon fibroblasts, CCD-18Co cells, 
served as control normal cells. The ideal targeting moiety should not exert notable 
toxic effects on normal cells/tissues. It should also be used at concentrations that 
caused minimal cytotoxicity to the cancer cells so as not to complicate the screening 
of the drug delivery system. To determine the sub-cytotoxic concentrations of WGA 
for subsequent experimentation, the MTT assay was applied to evaluate the 
cytotoxicity of WGA at concentrations ranging from 0.1 to 200 μg/ml against the 
Caco-2, HT-29 and CCD-18Co cells. WGA showed a concentration- and 
time-dependent cytotoxicity against the 3 cell lines studied. It was cytotoxic to all 
three colon cell lines at concentrations ≥ 50 µg/ml, particularly upon prolonged 
exposure of 72h. 
 
Cancer-cell selectivity of WGA was also evaluated by comparing its uptake, in the 
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form of fWGA, by the Caco-2, HT-29 and CCD-18Co cells as a function of time. The 
uptake results showed a higher fWGA uptake by the colon cancer cells compared to 
the colon normal cells. The uptake profile typically showed a rapid initial uptake rate 
followed by a slower rate of uptake after 30 min. WGA uptake by the Caco-2 cells at 
the loading concentration of 20 µg/ml was about 2.5 and 3.0 times higher than those 
of the HT-29 and CCD-18Co cells, respectively. Although the Caco-2 cells showed a 
consistent 1.5 fold higher uptake of fWGA compared to HT-29 cells at all time points 
examined, the HT-29 cells also exhibited a substantial capacity for WGA binding, the 
cellular WGA uptake reaching about 50% of the initial fWGA load administered to 
the cells at the loading concentration of 10µg/ml at 2h. The rank order of fWGA 
uptake was Caco-2 > HT-29 > CCD-18Co cells. Higher cancer-to-normal cellular 
uptake of WGA was observed. The selectivity of WGA for agglutination with the 
colon cancer cells relative to the normal fibroblast CCD-18Co cells underscored the 
potential for formulating a WGA-mediated targeting chemotherapeutic drug delivery 
system for the treatment of colon cancer. 
 
An ideal way for understanding glycosylation changes during oncogenesis of colon 
cancer is to map the full-range of glycosylation patterns of various colon cancer cells 
and normal colon cells. In order to use WGA as a tumor-targeting ligand, there is a 
need to establish the expression profile of its receptor glycoproteins in target cells. In 
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this study, lectin blot analysis was used to investigate the surface and intracellular 
glycoproteins expressed in the model colon cells. Our results confirmed the 
differential expression levels of N-acetyl-D-glucosamine-containing glycoproteins in 
the cell membrane and intracellular compartments of Caco-2, HT-29 and CCD-18Co 
cells. The ranking order of expression of these glycoproteins in the cells was HT-29 > 
Caco-2 > CCD-18Co, suggesting that normal colon cells may express lower levels of 
WGA-recognizable glycoproteins than the cancerous colon cells. fWGA cellular 
uptake data supported the hypothesis that WGA-binding residues were expressed in 
the glycocalyx of the three cell lines, particularly the Caco-2 and HT-29 cell lines. 
The existence of N-acetyl-D-glucosamine proteins in the cell membrane could 
facilitate WGA-membrane receptor recognition and enhance the endocytosis of 
WGA. 
 
WGA-conjugated, paclitaxel-loaded PLGA nanoparticles were prepared by a 
modified emulsion solvent evaporation method (MESE). As shown previously by our 
laboratory, and confirmed in this study, the MESE was a simple and reproducible 
method for the preparation of WGA-conjugated PLGA nanoparticles. The in vitro 
anticancer activity of WNP was evaluated by determination of the IC50 of the 
formulation against cancer and normal colon cells. Control formulations included 
PNP, which comprised paclitaxel-loaded PLGA nanoparticles without WGA 
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conjugation, and P/CreEL, similar to the conventional clinical formulation of 
paclitaxel. In vitro anti-proliferation studies of WNP against the three colon cell types 
suggested that the incorporation of WGA enhanced the cytotoxicity of the 
paclitaxel-loaded PLGA nanoparticles against the cancer cells. WNP was significantly 
more cytotoxic towards the Caco-2 and HT-29 cells than the CCD-18Co cells at 72h, 
which was in keeping with the cellular uptake data. This indicated that the boosted 
cytotoxicity observed for WNP was a result of enhanced intracellular paclitaxel 
concentration. The IC50 of paclitaxel when delivered as WNP against the Caco-2 and 
HT-29 cells were, respectively, 1.6- and 4.9-folds lower than those of P/CreEL after 
72h incubation. PNP was more cytotoxic against the colon cancer cells than against 
the CCD-18Co cells at 24h incubation, but the differential cytotoxicities were no 
longer apparent when the incubation time was prolonged to 72h. The conventional 
formulation, P/CreEL did not exhibit clear differential cytotoxicity profiles towards 
the cancerous and normal colon cells at 24h and 72h.  
 
The greater efficacy of WNP correlated well with the higher cellular uptake and 
sustained intracellular retention of paclitaxel associated with the formulation. The 
cellular uptake and retention efficiency for WNP might be attributed to the 
over-expression of N-acetyl-D-glucosamine-containing glycoprotein on the colon cell 
surface. Caco-2 and HT-29 cells showed preferential uptake of WNP compared to 
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PNP, suggesting that WGA conjugation to the PLGA nanoparticles was advantageous 
in facilitating the nanoparticle uptake by the cultured colon cancer cells. Paclitaxel 
uptake from the WNP formulation at 2h incubation was the highest in the Caco-2 cells 
compared to the other two cell lines. Confocal study confirmed that most of the 
cell-associated fluorescence was located intracellularly. The implication is that WNP 
was successfully taken up into the cells. In the presence of free WGA, the uptake of 
the WNP was inhibited. This indicated that the cellular uptake was mediated by 
WGA. 
 
Internalization of WNP by Caco-2 cells, with co-localization with endo-lysosomes in 
30 min incubation, was demonstrated. The intensity of green fluorescence in the 
cytoplasm increased with incubation time, which correlates with the increasing 
amount of internalized WNP with time. Using Lysotracker Red and FITC-WGA as 
markers, we were able to show that the internalized WNP was delivered to the 
endo-lysosomes. Escape of WNP from the endo-lysosomal compartment was 
implicated, together with the release of paclitaxel from the nanoparticles into the 
cytoplasm. Endo-lysosomal escape of WNP might be attributed to the selective 
reversal of the surface charge of nanoparticles. However, this needs to be confirmed 
by further experiments. The induction of apoptosis, together with an arrest of the cell 
cycle at the subG1 and G2/M phases, was observed after 24h exposure to WNP. By 
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comparison, P/CreEL and PNP at equivalent paclitaxel doses produced a lower level 
of apoptosis under the same test conditions.  
 
In order to evaluate the effect of mucin on the intracellular delivery of WNP, a 
mucin-secreting colon cancer cell line, LS174T, was used in this study. Alcian 
blue/PAS staining showed both acidic and neutral mucins were produced by the 
LS174T cells after 6 days of culture. Lectin blot results confirmed the presence of 
higher levels of WGA-binding glycoproteins both in the cell membrane protein 
fraction and the cytoplasmic protein fraction of the 6-day culture compared with that 
of the 3-day culture. However, the 2 cell cultures showed no significant differences in 
the cellular uptake of paclitaxel from the WNP formulation, indicating that the mucin 
may not be a barrier for the uptake of WGA-conjugated nanoparticles by the LS174T 
cells. The MTT assay showed the three paclitaxel formulations, WNP, PNP and 
P/CreEL, to have comparable in vitro cytotoxicity against the LS174T cells after 24h 
incubation. However, differential cytotoxicites against the LS174T cells were 
observed when the incubation time was prolonged to 72h, with WNP exhibiting 
greater cytotoxicity compared to PNP and P/CreEL. The enhanced cell-killing effects 
might due to the retention of WNP through the interaction of WGA and the mucin 
glycoproteins. FRAP experiments suggested that fWNP was capable of diffusing 
through the mucus layer of LS174T cells slowly. The mobility of fWNP in the mucin 
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layer would not only help the particles stay close to the cells, thus increasing the 
concentration gradient of the drug, but also enabled the particles to be transported into 
the cells. 
 
To summarize, WNP had superior in vitro anti-proliferation activity against the 
representative colon cancer cells. The enhanced cytotoxicity of WNP in the colon 
cancer cells could be attributed to a more efficient cellular internalization of paclitaxel 
via WGA-mediated endocytosis, and a more efficient retention of the drug within the 
cells. The in vitro studies indicate that WNP may serve as a promising carrier for the 
targeted delivery of paclitaxel to colon cancer cells, and that WGA could be a useful 
tool for the realization of colon-cancer targeting of chemotherapeutic agents. The 
present study has also provided some information on the glycosylation patterns of 
colon cells, interaction of WGA and its receptor glycoproteins, and the cellular 
trafficking of WNP in Caco-2 cells. These data may further advance the development 
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7. Limitation of the study and Future Directions 
Results from this project have shown that the conjugation of WGA onto PLGA 
nanoparticles could improve the cytoadhesive and cytoinvasive properties of the 
nanoparticles and enhance the intracellular retention of paclitaxel by the colon cancer 
cells.  Our results confirmed WNP had superior in vitro anti-proliferation activity 
against the colon cancer cell lines, Caco-2 and HT-29, compared with the PNP and 
P/CreEL formulations, and it was less toxic against the normal CCD-18Co cells than 
against the cancer cells. The enhanced cytotoxicity of the WNP in the colon cancer 
cells could be attributed to a more efficient cellular internalization of paclitaxel via 
WGA-mediated endocytosis, and a more efficient retention of the drug within the 
cells. However, the final goal would be testing the efficacy of the WNP in vivo. For 
translating the present work from preclinical to clinical study, much work remains to 
be done. Studies may have to be done to confirm its targeting capability and efficacy 
in vivo. Biodistribution and pharmacokinetic/pharmacodynamic studies should also be 
conducted on the WNP in a suitable animal tumor model. In particular, it will be 
interesting to evaluate if the WNP is capable of trafficking across absorptive epithelia 
in vivo. In addition, safety is a major concern in clinical application. Cytotoxicity 
studies in our project were only conducted for 4 to 72 h exposure in a limited number 
of colon cancer and fibroblast cell models. Thus, the results may not truly reflect the 
effect of WNP in vivo. Long-term toxicity studies, particularly pertaining to the 
accumulation of the slowly-degrading PLGA and WGA, were also imperative to 




Chapter 7 Limitation of the Study and Future Directions 
In order to understand the influence of the interaction between mucin and particulate 
drug delivery system, a mucin-secreting colon cancer cell model LS174T was used in 
this project. The cytotoxicity, uptake and diffusion of WNP were investigated in this 
cell model. However, the mucus layer of the LS174T cell model may not be 
representative of the mucus lining in the human gastrointestinal tract. Moreover, the 
in vitro cell culture model is inadequate to produce a stable and reproducible mucus 
gel layer for measuring nanoparticle adherence and diffusion. Further studies will 
have to be performed in appropriate animal model(s) to confirm our findings, and to 
provide a greater understanding of the interaction between mucin glycoproteins and 
WNP in the more complex in vivo environments.  
 
The intracellular trafficking study indicated that about 30% of the endocytosed WNP 
was present in the late endo-lysosomes, and that WNP could escape from the endo-
lysosomal compartment into the cytosol. However, the escape mechanism, as well as 
the intracellular fate of the WNP, remains to be ascertained. It may be worthwhile to 
further explore the intracellular trafficking of WGA-conjugated nanoparticle systems 
to gain a deeper insight into the mechanism of the endocytosis process with a view to 
improve the uptake efficiency of WGA-conjugated nanoparticles in vitro and in vivo. 
More experiments are necessary to further elucidate the mechanisms of adhesion, 
internalization and intracellular distribution of WGA-conjugated nanoparticles. 
 
In this project, the glycosylation patterns of two colon cancer cells and a colon 
fibroblast cell line was investigated at the membrane protein level. Mucin production 
of LS174T cells was also studied by lectin blot. Further studies may be carried out to 
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investigate the glycoprotein and mucin expression at mRNA level in the cultured cells. 
To date, nine mucin genes have been identified, named MUC1 to MUC9 (Thornton et 
al., 2000).  Mucin expression is tissue- as well as cell-type specific, and it varies 
according to cell proliferation and differentiation. For instance MUC2 is confined to 
goblet cells while MUC3 is largely confined to enterocytes (VanKlinken et al., 1996). 
The characterization of mucin expression at the mRNA level may provide a better 
understanding of cancer-associated aberrant glycosylation patterns. More colon cell 
models or human colon tissues could be used to expand the range of glycosylation 
patterns studied so as to enable a fuller understanding of the glycosylation changes in 
colon cancer cells. This will aid in the prediction of the effectiveness of WNP in the 
treatment of colon cancer.  
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